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Summary 
 
Chronic conditions have become the global epidemic of the 20th and 21st century (1). 
Chronically ill patients follow a lifelong treatment of pharmacologic and non-pharmacologic 
components, which represents a huge burden (2) and leads to non-adherence (3). An 
awareness of the extent of the treatment non-adherence problem and its consequences on the 
individual and societal levels has led to dedicated efforts to research the problem in an attempt 
to remedy it. This dissertation deals with this topic and was conducted as a sub-project 
embedded in its two main constituting projects, ESPACOMP (the European Society for Patient 
Adherence, COMpliance, and Persistence) Medication Adherence Reporting Guideline 
(EMERGE) and Building Research Initiative Group: Chronic Illness Management and 
Adherence in Transplantation (BRIGHT). 
EMERGE is an initiative led by members and founding members of ESPACOMP (the 
European Society for Patient Adherence, Compliance, and Persistence). Its aim was to develop 
a guideline for reporting medication adherence research. The development of the guideline 
followed a structured process and incorporated input from topic experts worldwide. More 
details on EMERGE can be found in its published protocol, which is also the third chapter of 
this dissertation (4). 
BRIGHT is an international cross-sectional study of 1397 heart transplant (HTx) 
recipients, 100 clinicians and directors of 36 HTx centers in 11 countries on four continents. 
The main aims of the primary study were: 
1. To describe chronic illness management (CIM) practice patterns in centers, 
countries/continents in HTx 
2. To assess the prevalence and variability of non-adherence to treatment regimen, i.e. 
medication-taking, cessation of smoking, diet adherence, alcohol consumption, 
physical activity, sun protection and appointment keeping in HTx recipients in centers, 
countries/continents 
3. To determine which multi-level factors are related to immunosuppressive medication 
adherence 
4. To benchmark participating centers, countries and continents in relation to CIM 
practice patterns and non-adherence to health behaviors. 
More details on BRIGHT can be found in its published protocol (5). 
This dissertation is organized into 8 chapters as follows: chapter 1 introduces the 
treatment adherence topic and the knowledge gaps that are covered in the dissertation. It starts 
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by highlighting the treatment burden of chronically ill patients and, subsequently, how the 
problem of non-adherence arises. It moves on to clarify the consequences of non-adherence 
and its global burden in light of the increasing prevalence of chronic conditions worldwide. It 
then focuses on HTx recipients and their lifelong need to follow a complex treatment regimen 
of immunosuppressants (IS), other medications, lifestyle changes and follow-up care as an 
interesting subpopulation of chronically ill patients in which to investigate treatment 
adherence. In addition, the chapter introduces health behavior theories and briefly discusses 
the two models used in designing the BRIGHT study, namely the integrative model of 
behavioral prediction and the ecological model for medication adherence. A medication 
adherence taxonomy (6) that represents the core of EMERGE is then introduced. The 
taxonomy disentangles the medication adherence concept into three constituting phases: 
initiation, implementation and persistence. The chapter ends with an explanation of the 
knowledge gaps that the dissertation deals with and the rationale behind filling them.  
Based on these research gaps, chapter 2 summarizes the aims of the dissertation 
which are: 
1. To develop guidelines for reporting medication adherence research 
2. To assess and compare the prevalence of medication non-adherence (MNA) 
(implementation and persistence phases) to immunosuppressants  and co-medications 
in HTx recipients 
3. To describe the international practice patterns with regard to medication adherence 
assessment methods and intervention strategies across the transplantation continuum 
at HTx centers 
4. To assess the international prevalence and variability in non-adherence to six 
components of the post-HTx non-pharmacologic treatment (physical activity, sun 
protection, diet, alcohol use, non-smoking and outpatient follow-up visits) 
Chapters 3-7 present the studies fulfilling these aims as a part of the EMERGE and BRIGHT 
studies as follows: 
Chapters 3 and 4 of the dissertation represent EMERGE and focus on developing a 
guideline for reporting medication (pharmacologic treatment) adherence research. Given the 
observed inconsistency in reporting medication adherence research (7-9), a steering 
committee of members of ESPACOMP took the initiative to develop EMERGE as a way of 
normalizing the use of the abovementioned taxonomy in reporting such research. EMERGE 
was developed through a structured process following the guidance for developers of health 
research reporting guidelines (10). The EMERGE steering committee started the process by 
generating a pool of items that were used to formulate an initial item list. An international 
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group of medication adherence experts was then asked for their opinion on the initial list in 
two rounds of a Delphi study (11), the protocol of which is described in chapter 3. Based on 
pre-defined decision rules, the initial items could be deleted or modified, or new items could 
be suggested. The item list resulting from the Delphi study was approved after further fine-
tuning by ESPACOMP members during the ESPACOMP annual meeting in 2016 in Lisbon, 
Portugal. 
Chapter 4 presents the final guideline and explains the rationale behind the items on 
the final list. The final EMERGE item list is composed of two sections. The first section contains 
four items that represent minimum reporting criteria (medication adherence phase, 
operational definition, measurement, results) for medication adherence research. The second 
section consists of 17 items organized according to the sections of the most commonly used 
health research reporting guidelines (i.e. CONsolidated Standards Of Reporting Trials 
(CONSORT) (12), STrengthening the Reporting of OBservational studies in Epidemiology 
(STROBE) (13)) and avoids redundancy with them. EMERGE emphasizes the importance of 
reporting the phase(s) of medication adherence studied (initiation, implementation, or 
persistence). In this regard, it asks authors of medication adherence research articles to review 
literature, formulate research aims, use research methodology and report and discuss results 
appropriately for each medication adherence phase studied. In this way, consistency in 
reporting medication adherence research can be ensured, which in turn makes the reported 
research results more useful. 
Moving on to the HTx patient population, chapters 5-7 of the dissertation use data 
from the international BRIGHT study and focus on treatment adherence in HTx recipients as 
a subpopulation of chronically ill patients with a lifelong need for a complex treatment regimen 
and professional follow-up. 
First, the dissertation investigates the prevalence of non-adherence to all post-HTx 
medications. Given that all post-HTx medications (immunosuppressants and co-medications) 
are vital to good transplant outcomes (14-18), it is imperative that HTx recipients adhere to 
their prescribed medication. Chapter 5 describes and compares the prevalence of non-
adherence to both categories of medication in detail, focusing on the implementation and 
persistence phases and the corresponding dimensions (for the implementation phase: taking, 
drug holiday, timing and dose alteration). Using the Basel Assessment of Adherence to 
Immunosuppressive Medications Scale (BAASIS®) (19), medication non-adherence (MNA) 
was assessed through self-report in an interview with HTx recipients during their outpatient 
clinic follow-up visit. BAASIS consists of five items: four dealing with implementation 
dimensions with a recall period of four weeks and one on persistence with a recall period of 
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one year. For co-medications, the timing dimension was omitted as it is not always important 
to take all other medications within two hours of the prescribed time. 
Implementation MNA of IS was observed in 37.4% of the sample. More specifically, the 
prevalence of IS MNA was 17.3% for taking, 1.9% for drug holiday, 28.7% for timing and 1.6% 
for dose alteration. In view of discontinuation (non-persistence), we found a prevalence of 
0.5%. The prevalence of MNA to co-medications was: 23.9% for taking, 5.7% for drug holiday, 
28.7% for timing, 3.8% for dose alteration and 2.6% for discontinuation. Significantly higher 
levels of MNA to IS compared to MNA to co-medications was found in all the comparison 
dimensions: taking (OR=1.50; 95%CI=1.30-1.73, p<0.0001), drug holiday (OR=3.17; 
95%CI=2.13-4.73, p<0.0001), dose alteration (OR=2.46; 95%CI=1.49-4.06, p=0.0004) and 
discontinuation (OR=5.15; 95%CI=2.36-11.20, p<0.0001). These results point to the need for 
adherence-enhancing interventions for all post-HTx medications, and further assessment of 
the underlying mechanisms of the higher non-adherence to co-medications. 
The dissertation continues to discuss medication adherence in HTx recipients and in 
chapter 6 describes the process of management of adherence (practice patterns) (6) by HTx 
center clinicians internationally along the HTx continuum. On a 27-item questionnaire, 100 
clinicians from the 36 HTx centers (one to five per center) reported their practice patterns with 
regard to medication adherence assessment and intervention strategies at the following four 
time points: pre-transplant, immediately post-transplant, less than one year and one or more 
years post-transplant. Educational/cognitive, counselling/behavioral and 
psychosocial/affective intervention strategies were assessed. Clinicians’ responses 
(intervention present vs. absent; or incongruence in reporting intervention) were aggregated 
at the center level. 
Questioning patients (self-report) was the most commonly used adherence assessment 
method along the transplant continuum (75-88.9% of the centers). Pre-transplant, providing 
reading materials (82.9%) or instructions (68.6%), involving family or support persons in 
education (91.4%) and establishing partnerships (91.4%) were used most frequently. Training 
patients (during recovery) and cueing were more often applied during hospitalization (74.3%). 
After the first year post-transplant, except for motivational interviewing (25.7-28.6%), the 
number of adherence-enhancing strategies decreased. Given the observed decrease in 
medication adherence over time post-HTx (20) and the relatively stagnant long-term 
prognosis (21, 22), increased investment in long-term medication adherence-enhancing 
interventions is necessary. 
Besides medication, HTx recipients are usually recommended to make certain lifestyle 
changes and to attend regular follow-up appointments at an outpatient clinic. It is equally 
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important that they adhere to this non-pharmacologic treatment regimen (23). Chapter 7 
investigates the prevalence and between-country variability of non-adherence to this 
treatment regimen in HTx recipients using self-report. The non-adherence definitions used 
were: physical activity: <3 times/week 20 minutes’ vigorous activity, <5 times/week 30 
minutes’ moderate activity, or <5 times/week a combination of either intensity; sun protection: 
not “always” applying any sun protection; diet: not “often” or “always” following recommended 
diet(s); alcohol use: > 1 alcoholic drink/day (women) or > 2 drinks/day (men); smoking: 
current smoker or stopped <1 year before; follow-up visits: missing ≥1 of the last 5 outpatient 
follow-up visits. Between-country variability was assessed within each treatment component 
via chi-square testing. 
The adjusted study-wide non-adherence prevalence figures were: 47.8% for physical 
activity (95% CI [45.2-50.5%]), 39.9% for sun protection (95% CI [37.3-42.5%]), 38.2% for diet 
recommendations (95% CI [35.1-41.3%]), 22.9% for alcohol consumption (95% CI [20.8%-
25.1%]), 7.4% for cessation of smoking (95% CI [6.1%-8.7%]) and 5.7% for follow-up visits 
(95% CI [4.6-6.9%]). Moreover, significant variability was observed between countries in all 
treatment components except follow-up visits. These findings suggest a need for setting-
tailored adherence-enhancing interventions for the non-pharmacologic treatment. 
Chapter 8 of this dissertation summarizes these key findings and discusses them, 
including some reflections. These findings are: 1) developing EMERGE (European Society for 
Patient Adherence, COMpliance, and Persistence Medication Adherence Reporting Guideline), 
2) non-adherence to the post-HTx medication was prevalent in all of the investigated phases 
and dimensions and was significantly higher in co-medications than in immunosuppressants, 
3) regarding pre- and post-HTx adherence management practice patterns, questioning 
patients was the most commonly used adherence assessment method and the frequency of 
using almost all adherence interventions decreased post-HTx, and 4) non-adherence to the 
post-HTx non-pharmacologic treatment occurred in all the investigated health behaviors, in 
almost all country-behavior combinations, more frequently in some behaviors than in others, 
and more frequently in some countries than in others. 
The chapter concludes by stating that non-adherence to pharmacologic and non-
pharmacologic treatments remains a challenge that the healthcare system and all its 
stakeholders face. Having covered knowledge gaps on the levels of patients, clinicians, 
policy/decision-makers and researchers, this dissertation contributes to the ultimate goal of 
better treatment adherence and outcomes. Sound reporting of medication adherence research 
using EMERGE will increase the utility of the research results. At the same time, equipping 
clinicians with adequate measures of adherence could lead to better description of HTx-
recipients’ adherence behavior and the identification of those with inadequate adherence. 
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Accordingly, targeting all components of the post-HTx treatment regimen where non-
adherence occurs using tailored multicomponent adherence-enhancing interventions would 
be possible along the HTx continuum and should lead to better treatment adherence and 
outcomes. 
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Introduction 
 
1.1 Treatment adherence in chronic conditions and its 
consequences 
Patients living with chronic conditions, those lasting three months or longer (1), face 
the challenge of having to follow complex long-term therapies. These usually consist of 
medication (pharmacologic treatment), and lifestyle changes and follow-up with professional 
caregivers (collectively referred to as non-pharmacologic treatment). Beyond this, as the 
condition becomes an intrinsic part of their everyday life, they need to observe their conditions 
continuously (2) (self-monitoring) (e.g. monitoring blood glucose levels in the case of diabetic 
patients) and make informed decisions to manage them (2) (self-management) (e.g. adjusting 
their blood glucose level by administering an appropriate dose of their recommended 
treatment). Hence, living with one or more chronic conditions represents a 
tremendous burden for chronically ill patients and the issue of treatment non-
adherence arises. 
Adherence to long-term therapies, defined as the extent to which a person’s 
behavior corresponds with agreed recommendations from a health care provider (3), is 
essential for achieving better outcomes on individual and societal levels. However, the problem 
of treatment non-adherence is widespread. A meta-analysis of 520 studies on non-adherence 
to treatment regimens (4) prescribed by a non-psychiatrist physician, reported an average non-
adherence prevalence of 20.6% for medications, 28% for exercise, 30.3% for health behaviors, 
34.1% for appointment keeping and 60.7% for diet. Poor adherence or non-adherence is 
associated with worse patient outcomes (e.g. slower or no improvement in the treated 
condition, preventable emergency department visits, hospitalizations, mortality) and, 
correspondingly, worse societal outcomes (e.g. higher disease burden, lower 
productivity, increased healthcare utilization) (5-8). For example, a meta-analysis of 44 studies 
on cardiovascular diseases (CVD) attributed 9.1% of CVD events in Europe to poor adherence 
to CVD medication (9). In the same way, lower adherence to lipid-lowering drugs was 
associated with worse prognosis, survival and quality of life (10). In heart transplantation 
(HTx), non-adherence to immunosuppressants was associated with higher incidence of 
transplant coronary artery disease (11). Although less investigated than medication non-
adherence (MNA), non-pharmacologic treatment non-adherence has similarly detrimental 
consequences. Non-adherence to a sodium-restricted diet, for example, was found to be 
associated with greater symptom burden and shorter cardiac event-free survival in patients 
with heart failure (12). Similarly, non-adherence to follow-up visit appointments was a 
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significant risk factor for kidney graft loss (13) and late acute cardiac graft rejection episodes 
(14) in transplant recipients. 
A recent systematic review of 79 studies (15) investigated the annual costs caused by 
medication non-adherence, including pharmacy, inpatient, outpatient, emergency department 
visit, medical and hospitalization costs. It found that the total annual cost of medication non-
adherence per person across all disease groups ranged from $949 to $52,341, adjusted to the 
2015 US$ value to allow for a comparison between studies. On the country level, the annual 
cost of medication non-adherence was estimated to be $100 billion in the US (16). Similar 
studies on the cost of non-pharmacologic treatment non-adherence are lacking. 
 
1.2 Chronic conditions in the 20th and 21st centuries 
This burden of non-adherence consequences is aggravating due to the increasing 
prevalence of chronic conditions. Owing to technological advancements, chronic conditions 
have become the global epidemic of the late modern era. Advances in treating communicable 
(infectious) diseases have led to better survival and life expectancy (17). As a result, the 
proportion of older people in the population has been steadily increasing since the 20th century 
(18). At the same time, recent technological developments have commonly been accompanied 
with more risk factors for chronic conditions. For instance, an estimate of 45% of all deaths in 
the USA in 2000 were attributed to personal decisions (the majority of which were decisions 
related to risk factors for chronic conditions, e.g. smoking, having an unhealthy diet, 
insufficient physical activity, alcohol consumption), in contrast to only 5% in 1900 (19). The 
shift in the world’s population pyramid has led to prolonged exposure and 
technological advancements have led to more opportunities of exposure to risk 
factors of chronic conditions. Combined, these factors have led to a higher 
incidence of chronic conditions.  On the other hand, advances in controlling, not curing, 
chronic conditions have led to rising numbers of people surviving with these conditions 
(higher prevalence). Indeed, the prevalence of chronic conditions has been rising worldwide 
in an unprecedented fashion since the 20th century. In the US, for example, an estimated 50% 
of all adults had at least one chronic condition in 2012 (20). Worldwide, 22% of adults 18 years 
or older had hypertension and 9% had diabetes in 2014 (21). Thus, problems related to 
chronically ill patients (including treatment non-adherence) represent a major challenge to the 
current healthcare system. 
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1.2.1 Heart transplantation as a chronic condition 
One subpopulation of chronically ill patients is heart transplant (HTx) recipients. HTx 
as a treatment option for patients with end-stage heart disease has become more successful in 
terms of graft and recipient survival as a result of advancements in surgical techniques, 
immunosuppression and infection control (22). Based on this improvement in outcomes, the 
demand for HTx has been increasing. According to the Global Observatory on Donation and 
Transplantation (23), the number of heart transplants performed globally (107 countries) rose 
from 2,259 in 2000 to 7,012 in 2015. Consequently, HTx recipients represent an interesting 
and increasing patient population. HTx, though, is more a life-sparing treatment than a 
complete cure. Indeed, by receiving a transplant, patients gain improvement in their cardiac 
and consequently physiological and physical functions but remain reliant on a lifelong 
treatment regimen, professional healthcare and self-monitoring and -management. In other 
words, by receiving the cardiac transplant, HTx recipients move from one illness 
state (end-stage heart disease) to another less severe but chronic state (post-
HTx). 
Undeniably, HTx recipients, as chronically ill patients, require lifelong adherence to a 
regimen of immunosuppressants (24). One problem with immunosuppressants, however, is 
that they are associated with several side effects and might lead to other chronic conditions. 
More specifically, common comorbidities attributed to immunosuppressants intake at 5 years 
following HTx include renal dysfunction (51.1%), diabetes (35.5%) and malignancy (15.9% all 
types combined; skin malignancy has the highest prevalence at 9.5%) (25). Furthermore, HTx 
recipients might have other chronic conditions pre-HTx that continue to post-HTx. As a result, 
recipients’ post-HTx treatment regimen typically includes other long-term medication and the 
lifelong adoption of a non-pharmacologic treatment regimen (24) to avoid, or at least delay, 
the incidence or progression of other comorbidities and to ensure favorable outcomes. This 
non-pharmacologic treatment regimen includes being physically active, not smoking, limiting 
alcohol intake, applying sun protection, following certain dietary recommendations (e.g. a low-
salt or low-fat diet) and infection control (24). Furthermore, HTx recipients need to be 
regularly followed up by specialized healthcare professionals to monitor their condition, check 
them for any sign of cardiac graft rejection, train them in self-management and follow up on 
and adjust their treatment plans (24). In addition, as chronically ill patients, they need to 
monitor their condition continuously and make informed decisions to adjust their treatment 
accordingly. 
For these reasons, HTx recipients represent a particularly susceptible 
population of chronically ill patients who follow a complex therapeutic regimen 
and who are likely to become non-adherent (26) to any of their treatment 
  Chapter 1 
 
14 | P a g e  
 
components. Given the importance of this treatment regimen to the survival of HTx 
recipients and their cardiac grafts, and given the scarcity of the cardiac grafts available 
compared to the number of patients on transplantation waiting lists (27), adherence to the 
treatment regimen is critical (11, 28). Worth introducing in this regard is BRIGHT (Building 
Research Initiative Group: Chronic Illness Management and Adherence in Transplantation), a 
cross-sectional study of 1397 HTx recipients, 100 clinicians and directors from 36 HTx centers 
in 11 countries and four continents. Assuming that treatment non-adherence is multifactorial, 
this study investigated the prevalence and multi-level correlates of treatment non-adherence. 
This dissertation uses data from BRIGHT to achieve some of its aims. Hereinafter, theories 
and models constructed to explain treatment (health behaviors) adherence will be introduced 
briefly while highlighting the two models used to design the BRIGHT study. After that, the two 
major treatment components (pharmacologic and non-pharmacologic) will be dealt with 
separately while highlighting knowledge gaps in each component. Adult HTx recipients will be 
focused on as a population of interest with the goal of describing the processes of adherence to 
treatment and management of adherence (29) in this patient population to determine possible 
system leverage points as a step towards enhancing their outcomes. 
 
1.3 Health behavior theories and ecological models 
Several health behavior theories have been proposed as an explanation of how patients 
enact health behaviors or follow prescribed treatments (30). Examples of such theories include 
the theory of planned behavior (31), the social cognitive theory (32), the health belief model 
(33) and the integrative model of behavioral prediction (IMBP) (34). While these theories have 
often been criticized (35, 36), they could provide foundations for conceptualizing human 
health behavior dynamics. For instance, the IMBP, a model of health behaviors that integrates 
many factors from other models, depicted in figure 1.1, posits that the most proximal 
determinant of a person’s behavior is intention. In this model, this cause-effect relationship 
between intention and behavior is moderated by a person’s skills and abilities and other 
environmental factors. IMBP proposes that an individual’s attitudes, norms and self-efficacy 
are, in turn, determinants of intention and affected by a multitude of other variables including 
a person’s demographic and cultural variables. 
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These theories, however, are partial in their views of human health 
behaviors. They focus mostly on patients, and rarely consider factors beyond as affecting 
patients’ health behaviors (31-33, 37, 38). In fact, although these theories consider external 
factors, their focus tends to be on patients’ perceptions of the factors or the patients’ ability to 
enact the behavior in the presence/absence of the factors, rather than on the direct effects of 
these factors on behavior. In other words, most of the health behavior theories have focused 
predominantly on the psychological dynamics of the individual’s health behavior. A more 
holistic view of health behavior and its determinants would be more suitable since patients, as 
individual actors, do not behave in a vacuum but rather in a multi-level environment that 
influences their actions. 
Figure 1.2 presents an example of an ecological model for medication adherence (39). 
It classifies determinants of medication adherence into four categories (levels), namely: 
patient, micro, meso and macro. On the macro policy level, for example, access to healthcare 
(e.g. drug dispensing) with its dimensions of availability, affordability, accessibility, adequacy 
and appropriateness can play a significant role and has a direct effect on the patient’s 
adherence to health behaviors (e.g. medication-taking). Ecological models of health 
behaviors emphasize the environmental and policy contexts of behavior, while at 
the same time integrating social and psychological influences (40). Remarkably, 
although these factors may be easily categorized and labelled, they must be regarded as 
dynamic and interacting, rather than as separate or layered. As such, ecological models have 
more utility than health behavior theories as a functional starting point for understanding the 
Figure 1.1: The Integrative Model of Behavioral Prediction 
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behavior and developing multicomponent interventions that target several of its determinants. 
In its conceptualization, the BRIGHT study used an ecological model of medication adherence 
into which the IMBP was embedded. 
 
 
 
1.4 Pharmacologic treatment adherence 
1.4.1 Medication adherence: definition and taxonomy 
Medication (pharmacologic treatment) adherence is defined (41)  as “the process by 
which patients take their medications as prescribed”. A taxonomy that describes 
adherence to medication (29) conceptualizes it as a process with three major 
components (phases), namely initiation, implementation and persistence. After 
being prescribed a medication, this process starts with treatment initiation, when the patient 
administers the first dose of the prescribed drug. Problems related to initiation of medication 
typically occur in the form of late or non-initiation, and they are collectively called primary or 
initial medication non-adherence (42). Implementation is defined as the extent to which a 
patient's actual dosing corresponds to the prescribed dosing regimen, from initiation until the 
last dose is taken (29). Suboptimal implementation of the dosing regimen can happen in the 
form of deviations from the prescribed dose or dose timing. Persistence refers to the length of 
time between initiation and the last dose (29). Persistence problems take the form of early 
discontinuation of the treatment without a physician’s order. 
1.4.2 Medication adherence research and its current state 
While the first recorded observation of treatment non-adherence dates back to 350 BC 
(43), records of peer-reviewed publications in the late modern era show that it has been a topic 
of research for over five decades since the early 1960s. It has been investigated in many disease 
Figure 1.2: An ecological model for medication adherence; 
Berben et al. 2012 
Micro
Meso
Macro
Health Care Policy
Patient
Health care provider
Health care organization
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areas and its scope has encompassed many focus points including, for example, 
conceptualizing and defining the construct (29), developing appropriate measurement 
methods and measures (44), describing the prevalence of MNA (9, 45), determining its 
correlates (46, 47) and consequences (15, 48) and developing interventions to circumvent the 
MNA problem (49). MNA as a health behavior, however, is a latent construct that represents a 
challenge to research precisely. 
A major obstacle to progress in medication adherence and adherence-
enhancing intervention research is, indeed, the inconsistency (50-52) in 
conceptualizing, defining and measuring the behavior and, accordingly, in 
analyzing and reporting the measured behavior. As a starting point, inconsistency in 
conceptualizing medication adherence hinders an understanding of the actual behavior being 
investigated. This is often the result of the common fallacy that medication adherence is a 
single and static construct (53). Logically, however, medication-taking is a set of several phases 
(as explained earlier in the taxonomy) with correspondingly numerous measurement methods 
and instruments to measure the behavior. Many researchers fail to separate these three phases 
when conducting research on adherence to medication. Consequently, defining, measuring, 
analyzing and reporting the behavior all suffer from inconsistencies. As a result, progress in 
medication adherence and adherence-enhancing intervention research has been impeded. 
Many intervention studies fail to raise the level of medication adherence (50) and many of 
those that do succeed fail to show corresponding improvement in outcomes (54). 
Pooling medication non-adherence rates in a meta-analysis such as the one mentioned 
above (4) is an example of the problem, as it combines different measures and operational 
definitions of MNA in pooled estimates that oversimplify the reality. As a matter of fact, in the 
same meta-analysis, investigating 513 studies revealed the use of 6 categories of measurement 
methods. Indeed, medication adherence measurement methods are broadly classified as direct 
or indirect, each class has various categories, and, respectively, each category has various 
measurement instruments (measures) (16, 55, 56). MNA rates that are based on different 
measurement methods and operational definitions are not directly comparable 
(57). As indicated by Gellad et al. (57), comparing studies reporting prevalence of non-
adherence to medications necessitates a clear definition and consistent measurement of the 
behavior. This will lead to appropriate analysis and clear reporting of the results of the analysis. 
Thus, proper inferences can be made based on clearly reported results. 
1.4.2.1 Medication adherence research reporting & reporting guidelines 
As explained above, inconsistency in conceptualizing, defining, measuring and 
analyzing medication adherence data leads to suboptimal reporting of the behavior. Indeed, 
several peer-reviewed publications have highlighted the need for more consistent and 
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transparent reporting of medication adherence research results (50, 51, 58-60). Although not 
specifically examined in this field, other health research reporting guidelines were shown to 
improve the quality of research reporting (61-63). Special guidelines for reporting medication 
adherence research have been developed before (42, 50, 64-66). Nevertheless, the quality of 
medication adherence research reporting is still unsatisfactory. This might be the result of a 
failure to adhere to the existing guidelines. In fact, a general theme was observed in a review 
of systematic reviews on adherence to reporting guidelines, in that 86% of the studies reported 
suboptimal levels of adherence to reporting guidelines (67). 
However, the current guidelines for medication adherence research have shortcomings 
that might also contribute to the present suboptimal reporting of this research. First, they do 
not build on a clear conceptualization of medication adherence that helps researchers to report 
their target medication-taking behavior transparently (50, 64-66). In addition, they show some 
overlap with the guidelines developed for general health research and thus do not have 
medication adherence research as their exclusive focus (64, 65). Moreover, they sometimes 
focus on the conducting of a study rather than on reporting its results (42, 50, 66). As a result, 
there is a need to develop a guideline specific to reporting medication adherence research that 
builds on a taxonomy such as the aforementioned as a starting point for consistent and 
transparent reporting (68). Based on this identified knowledge gap, this dissertation 
will propose a new guideline that remedies the shortcomings of the existing ones. 
Transparent reporting of medication adherence research will hopefully lead to 
the generation of more informative results that can be used to improve patient 
outcomes. 
1.4.3 Medication adherence after heart transplantation 
Beyond reporting medication adherence research, HTx recipients represent a 
particularly susceptible patient population that has to follow a complex lifelong medication 
regimen. One study showed that, on discharge from hospital post-HTx, the mean total number 
of medications HTx recipients were taking was 14.3 (69), and at five years’ post-HTx, about 
32% of the recipients took 16 medications or more (69), many of which are administered more 
than once daily. Most importantly, many of these medications are long-term and are crucial 
for their transplanted heart (immunosuppressants) and their other chronic 
conditions/comorbidities. As far as immunosuppressants are concerned, research on the HTx-
recipient population has shown that minor deviations from the immunosuppression schedule 
represent a risk factor for late acute rejections (28). In a five-year follow-up of 101 patients, 
HTx recipients who did not adhere to their immunosuppressants had significantly higher rates 
of cardiac graft coronary artery disease (53.3% vs. 40.9% for adherent HTx recipients) and 
higher, yet non-significant, rates of late acute rejection (11.8% vs. 2.4%), re-transplantation 
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(13.3% vs. 2.5%) and mortality (11.8% vs. 10.7%) (11). With regard to other post-HTx long-term 
medications, non-adherence to antidiabetics and antineoplastics, medications for two of the 
most common post-HTx complications, was found to be associated with higher morbidity, 
mortality and resource use (70-72). Nevertheless, medication non-adherence in HTx 
is prevalent and has been observed since the early days of HTx development (73) 
and continues today (74). 
1.4.3.1 Post-HTx adherence to immunosuppressants and co-medications 
Despite the recognized relationship between all post-HTx medication 
(immunosuppressants and co-medications) and HTx recipients’ outcomes (11, 
28, 41), research investigating adherence to all post-HTx medication is limited. 
Four studies (75-78) investigated MNA prevalence to co-medications separately yet without 
clarifying the actual phase of medication adherence investigated, a factor that impeded the 
identification of a target behavior for further research. One study (79) investigated self-
reported implementation non-adherence to all medication in HTx recipients and found an 
overall implementation non-adherence prevalence of 36.7% and 39.2% to 
immunosuppressants and co-medications respectively. However, this study investigated 
medication non-adherence in HTx recipients at a single center. This limits the generalizability 
of the results to the global HTx-recipient population. A study comparing non-adherence 
rates to immunosuppressants and co-medications in a diverse international 
sample of HTx recipients, while specifying the phase of adherence studied, could 
provide a detailed adherence profile of the post-HTx pharmacologic treatment. 
This would support decision-makers in their choice of adherence-enhancing 
interventions. This dissertation aims to cover this knowledge gap. 
1.4.3.2 Pre- and post-HTx adherence management practice patterns 
As discussed above, ecological models of health behaviors provide a wide-ranging view 
of factors affecting the behavior. On the level of the healthcare organization providing post-
HTx follow-up care (meso-level), structural attributes of the setting and its care processes 
contribute, directly and indirectly, to the outcomes of HTx recipients (80). With regard to 
MNA, the healthcare organization can affect the behavior through its contribution to the 
process of “management of adherence” (29). Illustrated in figure 1.3, management of 
adherence is defined as “the process of monitoring and supporting patients' adherence to 
medications by health care systems, providers, patients and their social networks” (29). As 
shown in the figure, this process spans the continuum of medication-taking from the first to 
the last prescription and its correspondingly necessary medication adherence. 
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This process is particularly important for HTx recipients in light of their complex 
medication regimen and of previous research showing that MNA to immunosuppressants post-
HTx increases over time (28). As yet, it is not known how professional care for management of 
adherence is delivered along the HTx continuum internationally. This dissertation will 
cover this knowledge gap by describing the international practice patterns of HTx 
centers with regard to management of adherence along the HTx continuum. 
Results from this study should provide further insights into opportunities for 
optimizing post-HTx healthcare delivery on the meso-level. 
 
1.5 Non-pharmacologic treatment adherence in heart 
transplantation 
In order to prevent or delay the incidence of immunosuppressant-related side effects 
and other chronic conditions, lifelong follow-up and lifestyle modifications including weight 
control, physical activity, diet (e.g. low fat and low salt intake), abstinence from smoking or 
heavy alcohol intake and the use of sun protection are recommended for HTx recipients (24). 
In contrast to medication adherence, the evidence on non-pharmacologic treatment adherence 
in HTx is limited. Gaps in this topic include a lack of evidence-based guidelines for appropriate 
treatment doses (most of the existing guidelines are based on expert opinion) and a lack of 
appropriate and sensitive measures of adherence. This reflects on non-pharmacologic 
treatment non-adherence being far less studied in the population of HTx recipients. 
Figure 1.3: The process of adherence to medication and the process of management of adherence; 
Vrijens et al. 2012 
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Robust evidence of the prevalence of non-adherence to the post-HTx non-
pharmacologic therapeutic regimen is scarce. A meta-analysis performed in 2007  (81) showed 
non-adherence rates of 33.7 cases per 100 patient-years for physical activity, 28.1 cases for 
following a diet, 8.5 cases for attending clinic appointments, 4.9 cases for alcohol use and 3.2 
cases for tobacco use in HTx recipients. However, these estimates were based on a small 
number of available studies. Moreover, as clarified above in the case of medication adherence, 
pooling non-adherence estimates together raises a methodological issue because of the various 
operational definitions, measurement methods and sampling strategies used in the studies 
included in the meta-analysis. 
Beyond this 2007 meta-analysis, other more recent studies have used small samples or 
samples from single centers (82), or have focused on a single behavior, providing no evidence 
of variations in HTx recipients’ health behaviors between countries. This dissertation will 
cover this knowledge gap by describing the international prevalence and 
variability of non-adherence to the post-HTx non-pharmacologic treatment 
regimen, using consistent methodology. Describing non-adherence prevalence in 
a diverse multinational sample of HTx recipients allows a better understanding 
of target behaviors for adherence-enhancing interventions and complements the 
post-HTx medication adherence profile. 
 
1.6 Summary and synthesis of the knowledge gaps 
In summary, patients with chronic conditions usually follow a complex treatment 
regimen. HTx recipients represent an interesting subpopulation of chronically ill patients as 
their treatment encompasses a wide range of components including the following: 
administering many medications (polypharmacy), adopting certain lifestyles, following up 
with a professional healthcare giver, self-monitoring and self-management. Given the 
complexity and longevity of the treatment regimen, the problem of treatment (pharmacologic 
and non-pharmacologic) non-adherence arises. Certain knowledge gaps in the literature have 
been identified above and are used as the basis for this dissertation. Below, these knowledge 
gaps are summarized and the rationales for filling them are presented. 
First, numerous studies have been conducted in attempts to describe MNA, determine 
its predictors (modifiable and non-modifiable) and outcomes, and design interventions to 
solve the problem by targeting its modifiable risk factors. Nonetheless, many studies in 
medication adherence research lack a rigorous conceptualization of the 
construct (MNA), leading to suboptimal reporting of research results and a 
severe limitation of the usefulness of the results. The lack of medication adherence 
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research reporting guidelines that are built on a clear conceptualization contributes to this 
problem, and developing such a guideline is envisioned as an essential step in enhancing the 
transparency of reporting medication adherence research and, consequently, its utility. 
Second, HTx recipients’ pharmacologic treatment regimen consists of 
immunosuppressants and other long-term medication. After HTx, immunosuppressants 
usually become the focus of professional and non-professional healthcare as the key to 
preserving the cardiac graft and hence, patients’ lives. Nevertheless, death with a functioning 
graft is not uncommon among HTx recipients as a result of other comorbidities that develop 
before or after HTx. Based on the established relationship between medication adherence and 
clinical outcomes, ensuring adequate adherence to all post-HTx medication is essential. To 
date, no study has described MNA to immunosuppressants and co-medication in 
a representative sample of the international HTx-recipient population while 
defining the actual phases and dimensions of MNA that are being studied. Filling 
this gap would allow us to form a better understanding of the post-HTx medication adherence 
profile that could work as a starting point for developing adherence-enhancing interventions 
specific to the phases and dimensions in which MNA occurs. 
Third, other factors beyond patients’ control can affect their medication adherence 
behavior, according to the ecological model of medication adherence. Factors related to the 
healthcare organization providing post-HTx follow-up care include the organization’s care 
processes. Previous research has shown that MNA to immunosuppressants post-HTx increases 
over time, yet it is not known how the process of management of adherence by HTx 
follow-up clinicians is carried out internationally along the HTx continuum. 
Describing international practice patterns among HTx centers concerning management of 
adherence along the HTx continuum would provide further insights into opportunities for 
improvement in post-HTx healthcare delivery, with the aim of enhancing medication 
adherence and, ultimately, HTx-recipients’ outcomes. 
Finally, HTx recipients’ medication regimen is complemented by professional follow-
up and a range of lifestyle modifications (non-pharmacologic treatment regimen). As there is 
an established relationship between non-adherence to this treatment regimen and poorer 
HTx-recipients’ outcomes, it is envisioned that supporting HTx recipients with their non-
pharmacologic treatment regimen could contribute to better HTx-recipients’ outcomes. To 
date, no study has provided a broad view of non-adherence to the post-HTx non-
pharmacologic treatment regimen in an international sample, using uniform 
methodologies. Describing non-pharmacologic treatment non-adherence in an 
international sample could help decision-makers to prioritize their target behaviors for 
adherence-enhancing interventions.  
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Research aims 
 
Given the highlighted knowledge gaps, the aims of this dissertation are: 
1. To develop guidelines for reporting medication adherence research (Chapters 3 & 4) 
2. To assess and compare the prevalence of medication non-adherence (MNA) 
(implementation and persistence phases) to immunosuppressants and co-medications 
in heart transplant (HTx) recipients (Chapter 5) 
3. To describe the international practice patterns with regard to medication adherence 
assessment methods and intervention strategies across the transplantation continuum 
at HTx centers (Chapter 6) 
4. To assess the international prevalence and variability in non-adherence to six 
components of the post-HTx non-pharmacologic treatment (physical activity, sun 
protection, diet, alcohol use, non-smoking, and outpatient follow-up visits) (Chapter 7)
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ESPACOMP Medication Adherence Reporting Guidelines 
(EMERGE): A reactive-Delphi study protocol 
 
Abstract 
Introduction: Medication adherence is fundamental to achieving optimal patient 
outcomes. Reporting research on medication adherence suffers from some issues—including 
conceptualisation, measurement and data analysis—that thwart its advancement. Using the 
ABC taxonomy for medication adherence as the conceptual basis, a steering committee of 
members of the European Society for Patient Adherence, COMpliance, and Persistence 
(ESPACOMP) launched an initiative to develop ESPACOMP Medication Adherence Reporting 
Guidelines (EMERGE). This paper is a protocol for a Delphi study that aims to build consensus 
among a group of topic experts regarding an item list that will support developing EMERGE. 
Methods and analysis: This study uses a reactive-Delphi design where a group of topic 
experts will be asked to rate the relevance and clarity of an initial list of items, in addition to 
suggesting further items and/or modifications of the initial items. The initial item list, 
generated by the EMERGE steering committee through a structured process, consists of 26 
items distributed in 2 sections: 4 items representing the taxonomy-based minimum reporting 
criteria, and 22 items organised according to the common reporting sections. A purposive 
sample of experts will be selected from relevant disciplines and diverse geographical locations. 
Consensus will be achieved through predefined decision rules to keep, delete or modify the 
items. An iterative process of online survey rounds will be carried out until consensus is 
reached. 
Ethics and dissemination: An ethics approval was not required for the study according 
to the Swiss federal act on research involving human beings. The participating experts will be 
asked to give an informed consent. The results of this Delphi study will feed into EMERGE, 
which will be disseminated through peer-reviewed publications and presentations at 
conferences. Additionally, the steering committee will encourage their endorsement by 
registering the guidelines at the Enhancing the QUAlity and Transparency Of health Research 
(EQUATOR) network and other relevant organizations. 
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Strengths and limitations of the study 
• Incorporates the input of many topic experts across various disciplines and 
geographical areas. 
• Preserves subject anonymity and reduces the effect of dominant individuals. 
• Uses statistical analysis techniques to reduce the potential of group pressure for 
conformity. 
• Requires large blocks of time to administer several survey rounds and 
consolidate their output. 
• Has potential to mould opinions based on the received aggregate feedback. 
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Introduction 
Reporting research on medication adherence is suboptimal. Confusion prevails 
regarding the conceptual underpinning, adequate measurement, and analysis of medication 
adherence data, hindering scientific progress in this field [1, 2, 3]. Guidelines on the reporting 
of health research aim at enhancing publication quality and may focus on specific study 
designs, research areas, or sections of a report. Examples of such guidelines can be found on 
the website of the Enhancing the QUAlity and Transparency Of health Research (EQUATOR) 
network (www.equator-network.org), and include STROBE [4] (for observational studies in 
epidemiology), CONSORT [5] (for trials), and TIDieR [6] (for description and replication of 
interventions) guidelines. The introduction of such guidelines and their endorsement by 
professional societies and journals have proven to be helpful in enhancing the transparency 
and accuracy of health research reporting [7, 8]. 
There are existing published guidelines and recommendations focusing on medication 
adherence research [1, 9-12]. However, these guidelines overlap considerably with those 
developed for general clinical research and are, thus, not particularly specific for medication 
adherence research [9, 10]. Additionally, they do not build on a clear conceptualization of 
medication adherence [1, 9, 10, 12], and focus on study design rather than reporting [1, 11, 12]. 
Considering the shortcomings of the existing guidelines and the aforementioned deficits in the 
quality of medication adherence research, this field would benefit from specific reporting 
guidelines to boost the quality of reporting medication adherence research. 
A steering committee of members of the European Society for Patient Adherence, 
COMpliance, and Persistence (ESPACOMP, www.espacomp.eu) launched an initiative to 
develop ESPACOMP medication adherence reporting guidelines (EMERGE) that will tackle 
the abovementioned shortcomings in the following manner. Considering the conceptualization 
of medication adherence, the anticipated guidelines will build on the ABC taxonomy for 
medication adherence [13]. This taxonomy defines medication adherence as ‘the process by 
which patients take their medications as prescribed’. It divides this process into three 
interrelated phases: (1) initiation; (2) implementation; and (3) persistence, each demanding a 
clear operational definition and appropriate measurement and data analysis. Hence, setting 
this conceptualization as a standard for reporting medication adherence research is anticipated 
to remove the ambiguity surrounding medication adherence as a concept. Additionally, 
designing the guidelines attentively to avoid overlapping with the existing guidelines for 
general clinical research has a twofold benefit. First, it will steer clear of redundancy and, thus, 
any confusion that might arise accordingly. Second, it will allow the new guidelines to be 
applied to the different study designs and used in parallel with the general guidelines available 
for the corresponding study design. Finally, developing the guidelines as reporting guidelines 
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will help both the authors in figuring out the important elements to be reported about their 
research and the reviewers in critically appraising the quality of the studies. 
Developing reporting guidelines, however, requires input by experts from various 
scientific backgrounds and needs to be relevant across geographical regions. This is 
particularly applicable in the context of medication adherence, which is a multidisciplinary 
science ranging from behavioral sciences through statistics and clinical medicine to economics. 
Delphi methodology, as a means for consensus building [14], enables integration of input from 
a wide variety of experts. It achieves consensus through an iterative process of survey rounds, 
providing the opportunity for participants to revise their input in subsequent rounds based on 
collective group feedback from previous rounds. This method enables the neutral and efficient 
integration of feedback from different experts, is suggested as one of the 18 steps put forward 
by the EQUATOR network in their guidance on developing health research reporting 
guidelines [15] and has been used in developing many similar guidelines [16, 17]. 
This approach has many benefits [18, 19, 20]. First, the iterative nature of the study and 
the feedback process allows participants to reassess their initial judgments. Thus, consensus is 
reached through a gradual stepwise process based on rational thinking and input. Second, 
participants do not interact directly and remain anonymous to each other until the survey 
rounds end. Hence, group domination by the views of certain individuals is avoided. Third, 
when participants consider changing or sticking to their original opinion after checking group 
response, this decision is not affected by the desire to be seen concordant with senior or 
dominant individuals. Fourth, experts can participate asynchronously and do not need to be 
present together while answering surveys as they receive collective feedback along with new 
surveys, which can be conducted through a web-based platform. Accordingly, it is feasible to 
use this approach to involve geographically distant participants. Moreover, the controlled 
feedback minimizes the effect of noise, which can happen in face-to-face group discussions. 
Finally, the ability to use statistical analysis facilitates reaching a more objective consensus 
than that usually reached though face-to-face conversations. Consequently, the Delphi method 
is an appropriate method to include the knowledge of many experts to cover the numerous 
aspects of the medication adherence subject. 
Aim 
The aim of this Delphi study is to build consensus among a group of topic experts 
regarding an item list that will support developing guidelines for medication adherence 
research reporting. 
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Methods and analysis 
Overview of the study design 
The study implements a reactive-Delphi design [21] where a group of medication 
adherence experts will be provided, in the first survey round, with an initial list of 26 items that 
are specific to medication adherence research. They will be asked to rate the relevance and 
clarity of the items (on a scale from 1 to 4; 1 is the lowest relevance/clarity, 4 is the highest 
relevance/clarity), with a possibility of providing suggestions of modifications of the initial 
items, or new items to be added. After each round of survey, pre-defined decision rules will be 
applied to keep, delete, or modify the items. This reactive-Delphi design allows for reduction 
of effort needed from the experts and faster arrival at consensus compared to the traditional 
Delphi design where experts are asked to come up with all items themselves. 
The steering committee 
The committee driving this initiative to develop guidelines for reporting research on 
medication adherence (also the authors of this study protocol) are members and founding 
members of ESPACOMP. One of their major research interests is medication adherence. They 
represent a diversity of disciplines including biostatistics, health economics, health policy and 
management, health services research, medicine, nursing, pharmacy, pharmacology, and 
psychology. Some members of the committee were involved in development of the ABC 
taxonomy for medication adherence (BV, DH, and SDG). 
Role of the steering committee 
The steering committee developed the initial items and will select the sample of experts 
for this study. Based on the decision rules, the steering committee will also apply the 
corresponding actions after each survey round: (i) keeping or deleting an item based on 
relevance scores, and (ii) modifying the wording of items based on clarity scores and the 
suggestions provided by the experts. For items that will not have achieved consensus on 
relevance after the survey rounds will be stopped, the steering committee will decide on each 
item individually based on internal consensus among its members, taking into consideration 
the aggregate input provided by the expert panel. All of the abovementioned tasks of the 
steering committee are further detailed later in this protocol. 
Sample and sampling procedures 
A purposive sample of medication adherence experts will be included in the study. The 
size of the group of experts needed for participation in any Delphi study does not depend on 
statistical power as representativeness in such studies is assessed based on the quality of the 
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sample rather than its size [20]. Accordingly, the steering committee identified medication 
adherence experts based on the representation of disciplines and geographical locations. In 
concordance with other similar projects aiming at developing guidelines for reporting of health 
research [16, 17], the goal is to include a minimum of 20 experts in the final survey round. To 
compensate for possible initial refusal or attrition over rounds, oversampling was considered 
with a rate of 25% per round. With a literature-based average [22] of three rounds until 
consensus is achieved, the starting sample will be a minimum of 40 experts. 
More specifically, the Delphi participants need to be established experts in the field of 
medication adherence and satisfy all the following main selection criteria: 
1) having a minimum experience of five years in the field of medication adherence; 
2) having an established international profile in this field, recognized by scientific 
publications, policy reports and/or extensive participation in specialized topic 
conferences, meetings, or interest groups; and 
3) having good English proficiency to complete the surveys 
To ensure representativeness of all relevant disciplines and geographical locations, the 
following variability selection criteria will be applied: 
1. The starting sample will include participants from each of the following disciplines: 
a. Health services research 
b. Clinical research 
c. Statistics 
d. Medicine  
e. Nursing 
f. Pharmacy/pharmaceutical sciences 
g. Pharmaceutical industry 
h. Clinical pharmacology 
i. Pharmacoepidemiology 
j. Behavioural medicine/health psychology 
k. Journal editing 
l. Public health 
m. Health policy 
2. Geographical representation will be ensured by selecting experts from all continents. 
Each of the steering committee members will provide suggestions for experts to be 
included on the expert panel for the Delphi study based on the aforementioned criteria. 
Feedback and agreement on the proposed list by the whole steering committee will be sought 
before experts are invited to participate. The final choice of the experts to be included will be 
based on an optimal distribution and representation of experts in view of the sample selection 
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criteria (main & variability criteria) and will be moderated by two members of the steering 
committee (SDG, RH). Delphi participants who will complete all rounds of the study will be 
listed in the final publication of the reporting guidelines in an acknowledgment section. 
However, the study will be fully anonymized and participants will not be known to each other 
during the survey rounds. 
Generation of the initial item list 
The initial item list was developed and fine-tuned by the steering committee. First, a 
literature review was performed to identify existing medication adherence research guidelines 
[9-11] and recommendations [1, 12] by two members of the steering committee (RH, SDG). 
This information was summarized and discussed in an in-person meeting in Prague in 
November 2015 among all of the steering committee members. This discussion, guided by the 
ABC taxonomy for medication adherence as well as by a review of common sections of the 
existing reporting guidelines for health research reporting (e.g. STROBE, CONSORT), led to 
generating a pool of items. 
Using a stepwise review process, the steering committee reviewed and further fine-
tuned the items in view of relevance and clarity over four feedback rounds via e-mail and 
conference calls. Items were gradually enhanced and revised to focus exclusively on aspects 
relevant to medication adherence. Redundancy between items of the existing reporting 
guidelines for health research (e.g. STROBE, CONSORT) and items for reporting research on 
medication adherence was scrutinized and eliminated where needed. 
The resulting initial item list consists of 26 items distributed in two sections. The first 
section includes 4 items that reflect the conceptualization of medication adherence as put 
forward by the ABC taxonomy for medication adherence and represent the taxonomy-based 
minimum reporting criteria. The second section includes 22 items specific to medication 
adherence research reporting and organized in a way congruent with common sections of 
reporting guidelines for major study types (e.g. STROBE, CONSORT). 
Decision rules and definition of consensus on relevance and clarity of 
items 
Since the definition of consensus varies among Delphi studies according to the aims of 
each study, rating scales along with consensus rules for this study were inspired by the content 
validity index [23] as it simplifies the decision-making process as explained below. Square 
(A) in figure 3.1 shows how the below decision rules will work together and their possible 
outcomes. 
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Item-level decision-making rules 
Scores for relevance will be used to decide on keeping or deleting an item. Consensus 
on relevance of an item is defined as 70% of the experts in the sample giving this item a score 
of three or more on a scale from one to four (1: not relevant; 2: somewhat relevant; 3: quite 
relevant; 4: highly relevant) during any survey round. Hence, this item will be kept on the final 
item list. Consensus on irrelevance of an item is defined as 70% of the respondents giving this 
item a score of two or less during any survey round. Consequently, this item will be deleted 
from the item list. 
Scores for clarity of wording will subsequently guide fine-tuning of the wording of the 
respective items to be included on the list. For simplifying the procedures, only one rule will 
be used for consensus on lack of clarity, defined as 70% of the respondents giving this item a 
score of two or less on a scale from one to four (1: not clear; 2: somewhat clear; 3: quite clear; 
4: highly clear) during any survey round. Consensus on lack of clarity for any item will further 
lead to using comments provided by the experts to modify the wording of each corresponding 
item. This will be done by the steering committee after the rounds end. 
List-level decision-making rule 
One of the key methodologic criteria of Delphi studies is having a stoppage rule on when 
the survey rounds will stop [22]. For this purpose, a stoppage rule of having a consensus on 
relevance for 80% of all items on the list will be used. In other words, the Delphi rounds will 
be stopped once 80% of the items on the list at that point of time receive consensus on 
relevance (i.e. 80% of the items received a score ≥ 3 by 70% of the experts). This rule will be 
applied from the first round if no new items will be suggested or from the second round after 
the experts will have provided scores for any suggested new items. 
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Figure 3.1: An overview of the Delphi process 
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Study procedures 
Once the initial item list and the participants sample are ready, the study will start with 
a preparatory period of two weeks to set up the online environment of the survey and test its 
functionality. Afterwards, survey rounds will start and continue until the stoppage rule is 
fulfilled. An invitation for a feedback round will be sent to the expert group with a response 
deadline of two weeks after the invitation day. Reminders will be sent to those who won’t 
respond, or will respond partially. Each round will be followed by an additional period for 
summarizing and analysing the responses and integrating the results into the following version 
of the survey. An invitation for a next feedback round will be sent out as described before to 
experts who will have completed all rounds from the beginning until then. 
The surveys will be conducted and the responses will be collected online via a survey 
platform (SurveyMonkey®). Two member of the steering committee (SDG, RH) will be 
responsible for data collection and responding to possible inquiries from the experts. In case 
substantial issues are addressed by any member of the expert group, the other members of the 
committee will be consulted for advice and problem resolution. 
A more detailed explanation of the process is provided below: 
1. First survey round will consist of: 
a. providing a score for each of the items in view of relevance to the topic and 
clarity of wording 
b. justifying the scores chosen and/or suggesting modifications for each item – 
(optional – free-form text) 
c. suggesting additional new items – (optional – free-form text) 
Additionally, experts will provide information on their demographics, professional 
background, and specific areas of expertise in adherence research for descriptive 
purposes as well as confirming their eligibility in the first survey round. 
Scores provided for the items will be summarized by their percentages and 
frequency distribution and inclusion or deletion of items in the following version of the 
survey will be guided by the aforementioned decision rules. Comments on potential 
adaptations of item wording will be summarized and integrated by the steering 
committee where deemed relevant. 
If no new items are suggested and consensus on relevance is reached for 80% of the 
items on the initial item list, the survey rounds will be stopped. Otherwise, the scores 
and comments of items that will not have reached consensus on relevance will be 
presented in the following round and/or suggestions of new items will be summarized 
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and integrated into the following version of the survey. Further evaluation and decision 
making will follow the methodology described before. 
2. Second round: An adapted item list including the scores and comments of the initial 
items as well as any new items from the 1st round will be sent to the experts. They will 
be invited to: 
a. revise their opinion with new relevance and clarity scores, on the same scale as 
mentioned before, and comments for items that did not achieve consensus on 
relevance in the 1st round 
b. score each of the new items in view of relevance to the topic and clarity of 
wording, on the same scale as mentioned before 
c. justify the scores chosen and/or suggest modifications for each item – (optional 
– free-form text) 
If list-level consensus is not reached by the 2nd round, scores and comments will be 
summarized as described in the 1st round and integrated into the item list to be 
presented in further rounds until consensus is reached. 
3. Further rounds will consist of presenting consolidated feedback for all items that will 
not have achieved consensus on relevance in previous rounds with a chance for experts 
to revise their opinion accordingly with: 
a. new relevance and clarity scores for the remaining items 
b. justification for the scores chosen and/or modifications for each item – 
(optional – free-form text) 
Finally, results of the final round will be consolidated and presented to the steering 
committee for proceeding with further steps. The flowchart in figure 3.1 delineates the survey 
rounds based on the input and output of each round. 
Ethical and legal considerations 
Since this study does not use health data of individuals, an ethics approval is not 
required according to the Swiss federal act on research involving human beings. Participants 
in the Delphi study will be asked to provide informed consent to have their responses included 
in further analysis and dissemination of the results. Furthermore, they will be informed about 
confidentiality of the data and the corresponding legal obligations of not exposing such data to 
third parties. Additionally, they will be asked whether they would like to be acknowledged in 
the corresponding publications and dissemination of the guidelines. All data relevant to the 
study will be kept on password-encrypted computers which can be accessed by the steering 
committee only. 
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Further planning of guidelines development 
The list of items reached through this study will be integrated by the steering committee 
into the planned ESPACOMP medication adherence reporting guidelines (EMERGE). The 
guidelines will be disseminated through peer-reviewed publications, presentations at 
conferences of ESPACOMP and other relevant organizations, and registration of the guidelines 
with the EQUATOR Network. Endorsement of the guidelines by journals and relevant 
professional organizations will be encouraged. Two members of the steering committee (SDG, 
RH) will remain available to receive feedback and criticism after publication. Accordingly, 
further updates and revisions of the guidelines will be considered on an annual basis during 
ESPACOMP annual meetings, based on the EQUATOR guidance for developers of health 
research reporting guidelines. 
Outlook 
Medication nonadherence is a public health threat that causes poor patient outcomes 
and increased economic burden[24, 25]. The quality of medication adherence research as well 
as the quality of its reporting will determine the development and testing of effective and 
innovative solutions to enhance patients’ adherence to medications and is therefore of 
paramount importance to many stakeholders. EMERGE aim at guiding researchers to report 
relevant aspects of medication adherence research in a standard manner. The use of the 
guidelines, in combination with other existing guidelines like STROBE or CONSORT, is 
expected to facilitate this task and, subsequently, help research in medication adherence field 
advance towards achieving its ultimate goal of improved outcomes. 
Delphi study status 
The initial item list was developed and the online survey environment was set up and 
tested by the steering committee. The sample of experts was chosen and data collection (1st 
round) started in June 2016. 
Contributors 
All persons listed as authors contributed to preparing the manuscript and the 
International Committee of Medical Journal Editors (ICMJE) criteria for authorship were met. 
Specifically, the following contributions were made by the respective authors: RH contributed 
substantially to the conception and design of the study, and the acquisition, analysis, and 
interpretation of data for the work; drafted the work and revised it critically; approved the final 
version to be published; agrees to be accountable for all aspects of the work. JD-J, DAH, BV, 
IBW and LLZ contributed substantially to the acquisition, analysis and interpretation of data 
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approved the final version to be published; agrees to be accountable for all aspects of the work. 
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ESPACOMP Medication Adherence Reporting Guideline 
(EMERGE) 
 
Abstract 
Research on assessing or managing medication adherence applies approaches from 
observational, interventional, and implementation science that spans many disciplines and 
demands coherent conceptualization, valid methods, appropriate analyses, and complete and 
accurate reporting. To ensure such reporting, the European Society for Patient Adherence, 
COMpliance, and Persistence (ESPACOMP) Medication Adherence Reporting Guideline 
(EMERGE) recommends standard reporting approaches based on an accepted taxonomy. 
This guideline is derived from a literature review, a reactive Delphi study with 26 
medication adherence experts from many countries and disciplines, and feedback from 
ESPACOMP members. It is designed to supplement existing guidelines for health research 
reporting and is structured around 4 minimum reporting criteria and 17 items reflecting best 
reporting practice. By enhancing and harmonizing research reporting, EMERGE aims to 
advance research and, ultimately, patient outcomes. 
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Medication nonadherence is a major public health problem (1, 2), with significant 
health and economic consequences (1-4). For many conditions, taking medications as 
prescribed is crucial to achieve optimal outcomes (5-7). Despite more than 50 years of research, 
the evidence base for effective interventions that can be implemented in routine clinical care 
remains limited (8, 9). 
Research related to medication adherence applies approaches from observational, 
interventional, and implementation science across disciplines, including but not limited to 
medicine, pharmacy, nursing, behavioral science, sociology, pharmacometrics, biostatistics, 
and health economics (10). Unfortunately, inadequate research reporting often hampers 
interpretation of findings, complicates data abstraction for meta-analyses, and prevents study 
replication. Common problems include unclear or inconsistent definitions (11-14), inadequate 
measurement of adherence outcomes (7, 14, 15), suboptimal analyses (11-14), insufficient 
description of intervention delivery settings (15), and scant theoretical underpinnings (16). 
Previous efforts to improve reporting standards in adherence research (11, 17-20) have 
resulted in guidelines and recommendations that overlap with existing guidelines for health 
research reporting, such as CONSORT (Consolidated Standards of Reporting Trials) (21), 
STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) (22), and 
StaRI (Standards for Reporting Implementation Studies) (23). These recommendations 
deviate from an exclusive focus on medication adherence research (17, 19), include no clear 
conceptualization of medication adherence (11, 17, 19, 20), and are more concerned with 
conducting rather than reporting research (11, 19, 20). 
Weighing these shortcomings against evidence that guidelines endorsed by 
professional societies and journals enhance overall health research reporting (24-28), the 
European Society for Patient Adherence, COMpliance, and Persistence (ESPACOMP; 
www.espacomp.eu) developed the ESPACOMP Medication Adherence Reporting Guideline 
(EMERGE). Grounded in the conceptualization of medication adherence provided by a 
previously reported taxonomy (10), EMERGE aims to complement existing guidelines for 
health research reporting. It aims to increase the transparency and consistency of reporting by 
guiding researchers through processes specifically relevant to medication adherence. 
Taxonomy for Medication Adherence 
EMERGE adopts the previously reported taxonomy (10), which defines medication 
adherence as “the process by which patients take their medications as prescribed” and divides 
it into 3 interrelated yet distinct phases: initiation, implementation, and persistence (figure 
4.1). Medication nonadherence, such as late or incomplete initiation or non-initiation, 
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suboptimal implementation of the dosing regimen (for example, late, skipped, extra, or 
reduced doses or drug holidays), or early discontinuation (non-persistence), can occur in any 
of these phases. Each phase creates methodological challenges related to how medication use 
is operationally defined, measured, and analyzed. 
Figure 4.1: Conceptualization of medication adherence 
Development of EMERGE 
EMERGE was developed in accordance with recommendations of the EQUATOR 
(Enhancing the QUAlity and Transparency Of health Research) Network (www.equator-
network.org) for developers of guidelines for health research reporting (29). The methods for 
developing EMERGE have been previously published (30). In brief, a steering committee 
comprising 7 members of ESPACOMP (S.D.G., L.L.Z., J.D.J., R.H., D.A.H., I.B.W., and B.V.) 
led the project. The committee first convened in Prague, Czech Republic, in 2015, followed by 
4 rounds of feedback via e-mail and conference calls in 2016. It discussed a literature review of 
published adherence guidelines and a further review of existing reporting guidelines for health 
research (21-23, 31), yielding an initial pool of 26 items (that is, statements) organized per the 
sections of the reporting guidelines used most often (CONSORT and STROBE). To avoid 
redundancy and to facilitate EMERGE’s applicability across study designs, the committee 
considered overlap with existing guidelines throughout the development process (30). 
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The initial 26-item pool was the basis of 2 rounds of reactive Delphi surveys (32, 33). 
The committee selected and invited a purposive sample of 45 international experts (from 15 
countries and 6 continents) who represented diverse disciplines and fields engaged in 
medication adherence research (17 in clinical research, 14 in health services research, 13 in 
public health, 11 in medicine, 9 in behavioral medicine or health psychology, 6 in journal 
editing, 5 in health policy, 5 in pharmacoepidemiology, 5 in statistics, 4 in nursing, 4 in 
pharmacy or pharmaceutical sciences, 3 in clinical pharmacology, 2 in the pharmaceutical 
industry, and 6 in other fields; experts belonged to 1 or more disciplines). Of the 45 experts, 29 
participated in the first round (response rate: 64%). They evaluated each item for relevance 
and clarity and could comment, suggest further items, or modify the initial items. Guided by 
predefined rules (30) and qualitative comments from the survey experts, the steering 
committee reviewed and discussed the first-round results during a meeting in Húsafell, 
Iceland, in July 2016. 
Based on the agreed criteria, all 26 items evaluated in the first Delphi round were 
judged to be relevant (mean, 91% [SD, 5%] [range, 79% to 97%]) and clear (mean, 84% [SD, 
10%] [range, 59% to 97%]). Nevertheless, the experts’ qualitative comments and subsequent 
committee discussion presented opportunities to optimize the wording of several items. The 
committee excluded 5 items because of redundancy or inconsistency with other items from 
EMERGE or the main reporting guidelines. 
The remaining 21 items entered the second Delphi round, during which 26 of the 29 
experts (90%) who participated in the first round rerated the items for relevance and clarity. 
All items again cleared the threshold for relevance (mean, 93% [range, 85% to 100%]) and 
clarity (mean, 90% [range, 73% to 100%]). The qualitative comments allowed the committee 
to fine-tune the wording of several items, resulting in the 21-item list that was presented at the 
annual ESPACOMP conference in Lisbon, Portugal, in November 2016 and approved by a 
formal vote of all members. 
The study was funded by ESPACOMP. The EMERGE steering committee is composed 
entirely of ESPACOMP members, who designed EMERGE, wrote this article, and submitted it 
for publication. 
EMERGE 
EMERGE comprises 21 items organized in 2 sections (table 4.1). The first section 
includes 4 items outlining the minimum reporting criteria for medication adherence research. 
The following criteria need to be specified clearly: each phase of medication adherence studied 
(that is, initiation, implementation, and persistence); a precise operational or working 
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definition of each examined phase; the methods of adherence measurement used for each 
phase, along with information on measure performance (that is, validity, reliability, and 
potential bias); and the results of the analysis relevant to each phase. 
The second section of the guideline comprises 17 items that provide more detailed 
information on medication adherence reporting. These are organized according to the 
reporting guidelines for experimental and observational studies (that is, CONSORT and 
STROBE) (table 4.1). Building on the minimum reporting criteria, these items further 
highlight the importance of considering and distinguishing between the 3 phases of medication 
adherence (for example, items 3a-b [background or introduction], item 4a [study objectives or 
hypotheses], items 8a-b [statistical analysis], and items 10a-c [discussion]). Other items 
address areas that are often under- or unreported in adherence research. Item 3b, for instance, 
focuses on the need to clarify the rationale or framework guiding the study. Item 5a addresses 
information relevant to the setting where the study was done (such as characteristics of the 
health care system, health care organization, and health care team), and item 5c requests 
information on routine care related to the management of medication adherence. For 
intervention studies (items 7a-b), descriptions of both intervention and comparator groups are 
requested. Interventions should be described (if relevant) in the context of specified levels of 
the health care system (that is, patient or caregiver, health care provider, health care 
organization, and health care system). Further methodological details are requested pertaining 
to sampling (item 5b asks whether medication adherence is an eligibility criterion) and 
measurement (item 6a addresses the potential effect of the adherence measure on medication 
adherence). Information requested on statistical methods distinguishes between medication 
adherence as an outcome measure (item 8a) and its use as an explanatory variable (item 8b). 
Item 7b, which is relevant to implementation science, asks for information (when applicable) 
on any implementation strategy (34) that contributes to translation of a medication adherence 
intervention into clinical practice. EMERGE also reminds authors to include details in their 
results sections of how nonparticipation or dropout may relate to medication nonadherence 
(item 9a) or sample characteristics relevant to medication nonadherence (item 9b).
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Table 4.1: ESPACOMP Medication Adherence Reporting Guideline 
 
Item Recommendation Page/Line 
Number 
Minimum reporting criteria 
1a Phases of medication adherence: State the phase(s) of medication adherence studied (i.e., 
initiation, implementation, and persistence), and justify, where possible, focusing on this/these 
phase(s). 
– 
1b Operational definition: Provide the precise operational/working definition for each phase of 
medication adherence studied (i.e., initiation, implementation, and persistence). 
– 
1c Measurement: Specify the methods of measuring medication adherence (e.g., self-report, claims 
data, blood sampling, and electronic monitoring). Consider each phase studied (i.e., initiation, 
implementation, and persistence), with details on the performance of the measures, where 
applicable (e.g., validity, reliability, and potential bias). 
– 
1d Results: Describe the results of the analysis appropriate to each phase of medication adherence 
studied (i.e., initiation, implementation, and persistence). 
– 
   
Additional EMERGE items 
Abstract   
2a Present in the abstract, in as much detail as space permits, information on the 4 minimum 
reporting criteria (i.e., items 1a–1d). 
– 
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Item Recommendation Page/Line 
Number 
Background/introduction   
3a Summarize what is known about the topic with appropriate reference to the phase(s) of 
medication adherence (i.e., initiation, implementation, and persistence). 
– 
3b Describe the rationale and/or framework guiding the medication adherence study (e.g., 
theoretical framework and implementation science model). 
– 
Study objectives or hypotheses 
4a State the study objectives or hypotheses with reference to the phase(s) of medication adherence 
studied and context (patient population and setting). 
– 
Methods   
Design and participants   
5a Describe the setting in which the study was done. Refer to factors relevant to medication 
adherence, such as characteristics of the health care system, organization, and team. 
– 
5b State whether medication adherence was an eligibility criterion (e.g., inclusion/exclusion). If so, 
define the measures and rules used. 
– 
5c Describe routine care related to the management of medication adherence, if applicable (e.g., 
routine assessment of medication adherence, adherence support programs, and provider 
training). 
– 
Measurement*  
6a Measurement methods can themselves affect medication adherence (e.g., questionnaires, blood 
sampling, and electronic monitoring). Address this problem as appropriate. 
– 
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Item Recommendation Page/Line 
Number 
Intervention (where applicable) 
7a For intervention and comparator groups, describe each relevant level of the medication 
adherence intervention (e.g., health care system, organization, and provider and 
patient/caregiver). 
– 
7b Describe any implementation strategy that contributes to the translation (e.g., uptake, delivery, 
and sustainability) of the medication adherence intervention in clinical practice, if applicable. 
– 
Statistical analysis   
8a If medication adherence is an outcome variable, justify the statistical methods, given the 
characteristics of the variable (e.g., phases of medication adherence, data type, statistical 
distribution, data censoring, and longitudinal dependence). 
– 
8b If medication adherence is an explanatory variable, describe how it is related to the outcomes 
(e.g., causal pathway and temporal sequence). 
– 
Results†   
9a Determine whether nonparticipation and/or dropout are associated with nonadherence, and 
provide any relevant data. 
– 
9b Present sample characteristics relevant to medication adherence (e.g., those related to 
sociodemographics and therapy, condition, patient, caregiver, and health care team/health care 
system). 
– 
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Item Recommendation Page/Line 
Number 
Discussion   
10a Discuss study strengths and limitations with reference to the phase(s) of medication adherence, 
where applicable (i.e., initiation, implementation, and persistence). 
– 
10b Discuss the study findings in the context of existing evidence on medication adherence (e.g., 
theory, measurement, and intervention effects). 
– 
10c Discuss the generalizability (external validity) of the study findings with reference to the 
phase(s) of medication adherence, where applicable (i.e., initiation, implementation, and 
persistence). 
– 
 
 
ESPACOMP = European Society for Patient Adherence, COMpliance, and Persistence. 
 
* See item 1c. 
† See item 1d. 
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Discussion 
EMERGE was developed to help researchers improve the often methodologically weak 
(8, 35, 36) and suboptimum reporting of medication adherence research (11-13). Although 
EMERGE has the advantage of being applicable to many study designs and methods focusing 
on medication adherence, authors will combine EMERGE items with other appropriate 
guidelines for health research reporting (such as STROBE, CONSORT, and StaRI). 
EMERGE was developed through a consensus-based process involving a 
multidisciplinary group of international experts on medication adherence. Using the Delphi 
surveys, these experts provided 2 rounds of feedback on the relevance and clarity of each item. 
In addition to enhancing EMERGE’s relevance across diverse settings, their cooperation will 
facilitate guideline implementation. 
One of EMERGE’s major strengths is its grounding in a medication adherence 
conceptualization provided by a robust taxonomy (10). Since its publication, this taxonomy has 
greatly benefited the field of medication adherence research (37, 38) and has been broadly 
adopted and widely cited (39). It distinguishes between 3 phases of adherence: initiation, 
implementation, and persistence. EMERGE highlights the need to acknowledge and specify 
each phase as a distinct part of the process by which patients manage their medication 
regimens; each requires specific considerations regarding conceptualization, definition, 
measurement, and analysis. 
EMERGE items—with the 4 minimum reporting criteria at their core—reflect essential 
yet often poorly handled or omitted elements of medication adherence research reporting. 
These include omission or suboptimal definition of key terms (7, 11-13), use of suboptimal 
measures (15), and use of inappropriate analytic methods (11-13). EMERGE also highlights the 
need for other relevant and often neglected aspects of adherence research reporting, such as a 
clearly explained rationale or framework (16) and detailed information on the health care 
setting, including routine care (15). 
EMERGE includes an item relevant to implementation science, which complements 
the StaRI reporting guideline (23), in recognition of the importance of this discipline in 
advancing the field of medication adherence. Although several promising interventions have 
been developed to improve adherence (8, 35, 40), none have been easy to implement in clinical 
practice. We do not suggest that every study can or should include an implementation 
component, but we encourage researchers to plan studies with an eye toward implementation 
and sustainability. 
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The main limitation affecting EMERGE’s development is its primary focus on 
quantitative methods. However, the 4 minimum reporting criteria can also help those 
designing qualitative and mixed-methods research to align their focus and relevant 
methodological aspects with the adherence taxonomy (10). In addition, although user testing 
showed that EMERGE is easy to apply in combination with the main reporting guidelines, the 
advised combination might initially seem challenging. Following the 21 EMERGE items will 
yield thorough reporting of all matters common to medication adherence research, but journal 
word limits may sometimes restrict full reporting. Possible solutions include pre-publishing 
detailed methods and protocols and providing online-only supplements or appendixes. Finally, 
although we tried to guarantee representation of all continents, the international Delphi team 
included fewer experts from African and Asian countries. 
In addition to this article, dissemination and use of EMERGE will be enhanced by 
information available on the EQUATOR and ESPACOMP Web sites (www.equator-
network.org and www.espacomp.eu/emerge) and endorsed by a range of related journals and 
professional organizations. ESPACOMP will support regular updates of EMERGE to ensure 
timely propagation of lessons learned from its use, along with new developments in medication 
adherence science. 
In conclusion, implementation of EMERGE is expected to enhance the reporting 
quality of medication adherence research by standardizing approaches, reducing research 
waste, accelerating progress in this and related fields, and ultimately improving patient 
outcomes. 
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Higher prevalence of medication non-adherence to co-
medications than to immunosuppressants in heart transplant 
recipients:  
Findings from the international cross-sectional BRIGHT study 
 
Abstract 
Purpose: To assess and compare the prevalence of medication non-adherence (MNA) 
(implementation and persistence) to immunosuppressants and co-medications in heart 
transplant (HTx) recipients. 
Methods: MNA prevalence was assessed using BAASIS® (self-report) and compared using 
logistic regression in a 36-HTx-center 11-country 4-continent sample of 1397 HTx recipients. 
Findings: MNA was significantly (=0.05) higher regarding co-medications than 
immunosuppressants (implementation: taking 23.9% vs. 17.3% (OR=1.5), drug holiday 5.7% 
vs. 1.9% (OR=3.17), dose alteration 3.8% vs 1.6% (OR=2.46) and discontinuation: 2.6% vs. 
0.5% (OR=5.15)). 
Implications: Given the prevalent MNA to all post-HTx medications, adherence-enhancing 
interventions need to focus on the entire medication regimen. 
 
ClinicalTrials.gov identifier: NCT01608477  
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Background 
Heart transplant (HTx) recipients depend on complex life-long medication 
regimens(1) of immunosuppressants to prevent graft rejection and co-medications (e.g., 
antihypertensives, lipid-lowering drugs) to help prevent or treat long-term co-morbidities. 
Previous research showed that HTx recipients’ mean total number of medications at discharge 
post-HTx was 14.3(2). Five years post-HTx, 32% of patients were taking 16 medications or 
more(2), many administered more than once daily. Such a high treatment burden increases 
the risk of medication non-adherence (MNA)(3). In solid organ transplantation(4), MNA is 
defined as any “deviation from the prescribed medication regimen sufficient to influence 
adversely the regimen's intended effect” and is associated with suboptimal clinical and 
economic outcomes(4). 
As a process, medication adherence consists of three inter-related phases(5): initiation, 
implementation, and persistence. For HTx recipients, initiation occurs during hospitalization 
for transplantation, making it irrelevant in the context of nonadherence. Implementation non-
adherence involves multiple dimensions: taking (missing a dose or more); drug holiday 
(skipping ≥2 consecutive doses); timing (taking medication >2 hours before or after the 
prescribed time); and dose alteration (taking more or fewer pills than prescribed or changing 
dosages without a physician’s order). 
While considerable transplantation research has been devoted to immunosuppressant 
non-adherence (NA), co-medication NA is less studied(1). Four HTx studies(6-9) reported 
separate prevalence estimates of co-medication NA, but without distinguishing between the 
phases of adherence. This omission impedes identification of target behaviors for 
interventions. To the best of our knowledge, the only study(10) to investigate the prevalence 
of implementation NA to both medication categories in HTx recipients reported overall 
implementation NA prevalence of 36.7% and 39.2% to immunosuppressants and co-
medications respectively. However, that study’s single-center design limited the 
generalizability of its results to the HTx population. 
Accordingly, assessing MNA to immunosuppressant and co-medication 
implementation and persistence in a diverse sample of HTx recipients from various countries 
while distinguishing between the dimensions will clarify how HTx recipients manage their 
post-HTx medication regimens, while helping define target behaviors for adherence-
enhancing interventions. Therefore, the central aim of this study is to describe and compare 
the prevalence of MNA (in the implementation and persistence phases) to 
immunosuppressants and co-medications in an international sample of HTx recipients. 
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Methods 
This study is a secondary data analysis of the Building Research Initiative Group: 
Chronic Illness Management and Adherence in Transplantation (BRIGHT) study, a cross-
sectional study in 36 HTx centers in 11 countries on 4 continents. Detailed information on the 
BRIGHT study’s methodology is reported elsewhere(11). 
Sampling and data collection 
The data used for this analysis were collected via patient interviews during outpatient 
clinic visits. Using a stratified random sampling approach based on center size (number of 
annual HTx procedures), HTx recipients were eligible to participate if they were adults (≥18 
years at enrolment), were transplanted and undergoing follow-up for routine care at a 
participating HTx center, received HTx as a single-organ transplant, were first-time HTx 
recipients (no re-transplantation), were 1–5 years post-HTx, were able to read and understand 
one of the languages in which the study was conducted, and were willing and able to provide 
written informed consent. HTx recipients were excluded if they had participated in adherence-
intervention research or drug trials during the 6 months prior to inclusion or had received 
professional support for medication intake. 
Variables and measurement 
Implementation- and persistence-phase MNA were assessed during the patient 
interview (self-report) based on a recall period of four weeks for implementation and one year 
for persistence. The instrument used was the Basel Assessment of Adherence to 
Immunosuppressive Medications Scale (BAASIS®)(12), which is built around the most recent 
taxonomy for medication adherence(5). Administered in a non-threatening, non-judgmental 
manner to encourage truthful answers, the BAASIS® starts by asking the patient’s about their 
current immunosuppressant regimen, i.e., each medication’s name, dose, dosing frequency, 
and intake schedule. The MNA assessment process is described below. 
Assessment of MNA to immunosuppressants: Implementation is covered by 4 
yes/no items: taking, drug holiday, timing, and dose alteration. Persistence is measured by 
asking patients if, during the recall period, they stopped taking their medication completely 
without physician’s orders (yes/no). 
Assessment of MNA to co-medications: The BAASIS® instrument was adapted 
for co-medications where taking, drug holiday and dose alteration are the only assessed 
implementation dimensions as timing is less critical for the majority of these medications. 
Persistence to co-medications was assessed as with immunosuppressants. 
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Scoring of the BAASIS®: Within each of the measured MNA dimensions, each 
positive answer indicated an instance of MNA. To indicate the prevalence of non-adherence 
within each dimension, we calculated the percentage of HTx recipients answering positively. 
Additionally, for immunosuppressants, a positive answer to any of the implementation 
dimensions indicated an instance of overall implementation NA (summarized similarly as a 
percentage). 
Statistical analysis 
Data were summarized descriptively based on levels of measurement and distribution 
(i.e., frequencies, proportions, means (SD)). To avoid over- or underrepresentation of each 
country’s HTx recipient population, MNA prevalence was calculated as a weighted average. 
This was achieved by multiplying each national non-adherence prevalence by a weighting 
factor  corresponding to the ratio of the HTx recipient population in the corresponding country 
to that of all included countries during the period of the study’s data collection there (based 
on data from the Global Observatory on Donation and Transplantation, 
http://www.transplant-observatory.org). 
To compare between immunosuppressant and co-medication NA prevalence (taking, 
drug holiday, dose alteration, and discontinuation), we used logistic regression analysis by 
generalized estimation equations, adjusting for data clustering on the HTx recipient and 
center levels. As fewer than 2% of data were missing, pairwise deletion was used. The 
significance level was set at 0.05. Stata® 13 (StataCorp LLC, Texas, USA) was used for 
descriptive statistics and SAS® 9.4 (SAS Institute Inc., North Carolina, USA) for regression 
analysis. 
Results 
From the 36 participating HTx centers, 2523 patients were eligible for inclusion. We 
randomly invited 1677 to participate, of whom 1397 (83.3%) responded. Their characteristics 
are shown in table 5.1. The observed and weighted prevalence of MNA for 
immunosuppressants and co-medications is reported in table 5.2. 
Table 5.1: Sample characteristics 
Characteristic Value 
Age (N) 
 Years, mean (SD) 
1380 
53.7 (13.2) 
Gender (N) 
 Male, n (%) 
1390 
1011 (72.7%) 
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Characteristic Value 
Ethnicity (N) 
 Caucasian, n (%) 
1381 
1186 (85.9%) 
Education (N) 
 Primary school, n (%) 
 Secondary school, n (%) 
 Further education, n (%) 
 University, n (%) 
1377 
187 (13.6%) 
426 (30.9%) 
294 (21.4%) 
470 (34.1%) 
Employment status (N) 
 Employed, n (%) 
1391 
413 (29.7%) 
Marital status (N) 
 Single, n (%) 
 Married/cohabiting, n (%) 
 Divorced/separated, n (%) 
 Widowed, n (%) 
1387 
242 (17.5%) 
955 (68.9%) 
149 (10.7%) 
41 (3%) 
Time post-HTx (N) 
 Years, mean (SD) 
1395 
3.4 (1.4) 
Immunosuppressants (N) 
Calcineurin inhibitors 
 Tacrolimus, n (%) 
 Cyclosporine, n (%) 
IMDH inhibitors 
 Mycophenolate, n (%) 
 Azathioprine, n (%)  
Corticosteroids 
 Prednisolone, n (%) 
 Hydrocortisone, n (%) 
mTOR inhibitors 
 Everolimus, n (%) 
 Sirolimus, n (%) 
1389 
1325 (95.4%) 
879 (63.3%) 
452 (32.5%) 
1127 (81.2%) 
1066 (76.7%) 
61 (4.4%) 
710 (51.2%) 
698 (50.3%) 
13 (0.9%) 
263 (19%) 
199 (14.3%) 
64 (4.6%) 
N: number of patients with observations for the corresponding variable 
SD: standard deviation 
IMDH: inosine monophosphate dehydrogenase 
mTOR: mechanistic target of rapamycin 
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Table 5.2. Prevalence and comparison of medication non-adherence (MNA), implementation and persistence phases, to immunosuppressants and 
co-medications 
Adherence dimension 
Immunosuppressants Co-medications Logistic regression results 
Prevalence of MNA (BAASIS®)a 95%CIsb Prevalence of MNA (BAASIS®)a 95%CIsb OR 95%CIs P value 
n / N 
% 
(observed ) 
% 
(weighted) 
 
 
n / N 
% 
(observed ) 
% 
(weighted) 
 
 
 
 
 
 
Implementationa  
 Taking dimension 241/1392 17.3% 15.1% 13.2%-17.0% 333 / 1392 23.9% 21.2% 19.0%-23.3% 1.50 1.30-1.73 <0.0001 
 Drug holiday dimension 26/1392 1.9% 1.4% 0.8%-2.0% 79 / 1392 5.7% 5.1% 3.9%-6.2% 3.17 2.13-4.73 <0.0001 
 Timing dimension 395/1376 28.7% 26.2% 23.9%-28.5%        
 Dose alteration dimension 22/1387 1.6% 1.5% 0.8%-2.1% 53 / 1390 3.8% 4.0% 3.0%-5.0% 2.46 1.49-4.06 0.0004 
 Overall implementation 520/1392 37.4% 34.5% 32.2%-37.2%        
Persistenceb  
 Discontinuation dimension 7/1386 0.5% 0.6% 0.2%-1.0% 35 / 1390 2.6% 2.4% 1.6%-3.2% 5.15 2.36-11.20 <0.0001 
a 1. Taking dimension (omitting a single dose once or more during the prior 4 weeks) 
  2. Timing dimension (taking the medication >2 hours before or after the prescribed taking time once or more during the prior 4 weeks, only for immunosuppressants) 
  3. Dose alteration dimension (altering the prescribed amount of medication once or more during the prior 4 weeks without a physicians’ order) 
  4. Drug holiday dimension (skipping at least two consecutive doses once or more during the prior 4 weeks) 
b Discontinuation of medication use completely within the prior year without a physicians’ order 
BAASIS: Basel assessment of adherence to immunosuppressive medication scale, OR: odds ratio, CIs: confidence intervals of the weighted estimates 
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Medication non-adherence to immunosuppressants 
Calcineurin inhibitors were used by 95.4%, IMDH (inosine monophosphate 
dehydrogenase) inhibitors by 81.2%, corticosteroids by 51.2%, and mTOR (mechanistic target 
of rapamycin) inhibitors by 19% of the sample. Immunosuppressant implementation NA was 
observed in 37.4% of participants. More specifically, the immunosuppressant NA prevalence 
was 17.3% for taking, 1.9% for drug holiday, 28.7% for timing, and 1.6% for dose alteration. 
For discontinuation, we found a prevalence of 0.5%. 
Medication non-adherence to co-medications 
The prevalence of NA to co-medications was 23.9% for taking, 5.7% for drug holiday, 
3.8% for dose alteration, and 2.6% for discontinuation. 
Comparison between immunosuppressant and co-medication non-
adherence 
Overall we found significantly higher levels of NA to co-medications compared to that 
regarding immunosuppressants: taking (OR=1.50; 95%CI=1.30-1.73, p<0.0001), drug holiday 
(OR=3.17; 95%CI=2.13-4.73, p<0.0001), dose alteration (OR=2.46; 95%CI=1.49-4.06, 
p=0.0004), and discontinuation (OR=5.15; 95%CI=2.36-11.20, p<0.0001). Similar higher 
prevalence of co-medication NA was also observed at the national level in all countries and 
dimensions except the taking dimension in Belgium and Switzerland. 
Discussion 
This study showed, in a large international sample of HTx recipients, that post-HTx 
MNA is prevalent for both immunosuppressants and co-medications. Given the risk 
accompanying immunosuppressant NA vis-à-vis HTx outcomes(1, 2), and the limited 
forgiveness of immunosuppressants(1), this magnitude of MNA is worrisome and calls for 
interventions. Moreover, confirming the evidence from prior studies in HTx(3) and other 
transplant populations(4), we found a significantly higher prevalence of MNA to co-
medications than to immunosuppressants. A study in kidney transplant recipients(4) 
proposed the concept of self-regulation as an explanation, i.e., patients might classify their 
drugs according to their indication to two categories (strict vs. flexible) and adjust their 
medication intake accordingly based on the daily pill burden. This adjustment/regulation 
process is conceptualized(5) as a function of the representation of health threats, the targets 
set accordingly for ongoing coping, the procedures to regulate these targets, and the appraisal 
of coping outcomes. Whether this self-regulation model sufficiently explains the observed 
adherence differences remains to be confirmed. 
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This study has some limitations. First, given the main study’s many variables and large 
sample, MNA was measured via self-report, which is susceptible(6) to social desirability and 
memory biases. Second, the main study’s focus was on immunosuppressants. Accordingly, 
detailed data on individual co-medications (e.g., number and names of drugs, daily pill 
burden) were unavailable for this secondary analysis. For the same reason, investigating 
factors responsible for differences between immunosuppressant and co-medication NA 
prevalence was beyond the main study’s scope. Fourth, centers were eligible for inclusion only 
if they performed an average of ≥10 HTx procedures annually. Smaller centers might organize 
post-HTx care differently, possibly resulting in different MNA prevalence. Finally, timing and, 
hence, overall implementation NA could not be measured for co-medications, meaning no 
direct comparison with immunosuppressants was possible across all MNA dimensions. 
To summarize, our findings of significantly higher non-adherence to co-medications 
than to immunosuppressants call both for further investigation of the reasons behind this 
differential adherence and for the integration of adherence assessment and enhancement 
interventions for all medications in post-HTx care. 
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Practice patterns to improve pre- and post-transplant 
medication adherence in heart transplant centres: A secondary 
data analysis of the international BRIGHT study 
 
Abstract 
Background: As medication non-adherence is a major risk factor for poor post-transplant 
outcomes, we explored how adherence is assessed, enhanced and integrated across the 
transplant continuum. 
Aim: The aim of this study was to study practice patterns regarding pre- and post-transplant 
medication adherence assessment and interventions in international heart transplant centres. 
Methods: We used data from the Building Research Initiative Group: chronic illness 
management and adherence in heart transplantation (BRIGHT) study, a cross-sectional study 
conducted in 36 heart transplant centres in 11 countries. On a 27-item questionnaire, 100 
clinicians (range one to five per centre) reported their practice patterns regarding adherence 
assessment and intervention strategies pre-transplant, immediately post-transplant, less than 
one year, and one or more year post-transplant. Educational/cognitive, 
counselling/behavioural and psychosocial/affective strategies were assessed. Clinicians’ 
responses (intervention present vs. absent; or incongruence in reporting intervention) were 
aggregated at the centre level. 
Results: The adherence assessment method most commonly used along the transplant 
continuum was questioning patients (range 75–88.9%). Pre-transplant, all three categories of 
intervention strategy were applied. Providing reading materials (82.9%) or instructions 
(68.6%), involving family or support persons in education (91.4%), and establishing 
partnership (91.4%) were used most frequently. Post-transplant, strategies closely resembled 
those employed pre-transplant. Training patients (during recovery) and cueing were more 
often applied during hospitalisation (74.3%). After the first year post-transplant, except for 
motivational interviewing (25.7–28.6%), the number of strategies decreased. 
Conclusions: Across the transplant continuum, diverse adherence interventions are 
implemented; however, post-transplant, the frequency of adherence interventions decreases. 
Therefore, increased investment is necessary in long-term adherence interventions.  
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Introduction 
Medication adherence is crucial to successful long-term outcomes after transplantation 
(Tx).(1,2) Defined as ‘[the] process by which patients take their medication as prescribed’, 
medication adherence involves three components: initiation, implementation, and 
discontinuation.(3) Medication non-adherence may involve late or non-initiation of the 
prescribed regimen, suboptimal implementation of the treatment (not taking medications; 
drug holidays; wrong timing; dose reduction), and early discontinuation of treatment. 
Independent of the assessment method and operational definition used, the magnitude 
of medication non-adherence in heart Tx recipients is high. Using meta-analytical techniques, 
Dew et al.(4) reported a non-adherence rate of 14.5 cases per 100 patients per year. The Swiss 
Transplant Cohort Study, which assessed medication non-adherence along the transplant 
continuum in solid organ recipients, recorded self-reported non-adherence rates ranging from 
7.9% pre-Tx to 18.8% three years post-Tx in their heary Tx group.(5) Post-heart Tx, the self-
reported non-adherence rate to co-medications was 39.2%.(6) 
In end-stage heart disease, as well as after heart Tx, medication non-adherence is 
associated with poor clinical(1,2,7–9) and economic outcomes.(10) In addition, in heart Tx 
even minimal deviations from the prescribed dosing schedule have been linked with poor 
outcomes.(1,2) 
Given the serious risks of medication non-adherence and the limited forgiveness of 
immunosuppressive regimens, guidelines for heart Tx therefore indicate a need to integrate 
medication adherence assessment and interventions into routine transplant care.(11) 
However, no evidence is currently available as to how international practice guidelines are 
implemented along the heart Tx care continuum. Using a methodological approach similar to 
those used in cardiovascular care(12) and after solid organ(13) or stem cell Tx,(14) our research 
group cross-sectionally assessed post-transplant medication adherence in relation to practice 
patterns in heart Tx centres. In addition to mapping the adherence assessment methods used 
(e.g. direct observation, blood assay results and indirect measures (self-report, collateral 
report, pill count, prescription refill, electronic monitoring)), we noted whether the 
intervention strategies used to improve medication adherence were educational/cognitive, 
counselling/behavioural, or psychosocial/affective.(15) 
De Bleser et al.(15) defined these three intervention categories as follows: 
educational/cognitive interventions convey information verbally, in writing, and/or 
audiovisually, either individually or in group settings; counselling/behavioural interventions 
shape and/or reinforce target behaviours, support patients to participate actively in their own 
Chapter 6 
 
89 | P a g e  
 
care, increase their skill levels or improve their routines; psychosocial/affective interventions 
act on patients’ feelings, emotions and social support. We refer to combinations of these 
categories as mixed interventions. Previous medication adherence practice pattern studies(12–
14, 16) showed that, regarding adherence-enhancing intervention strategies, clinicians applied 
mostly educational/cognitive strategies. 
Given the scarcity of related international evidence, the objective of this study was to 
describe international practice patterns regarding medication adherence assessment methods 
and intervention strategies across the transplantation continuum among heart Tx centres. 
Data were collected first pre-transplant, then at three post-Tx measurement points, (i.e. during 
hospitalisation post-Tx surgery, less than one year, and one or more year post-transplant). 
Methods 
Design, setting and sample 
The present study’s design is a secondary analysis using data from the Building 
Research Initiative Group: chronic illness management and adherence in transplantation 
(BRIGHT) study,(17) an 11-country multicentre, cross-sectional study including 36 heart Tx 
centres. The investigation conforms with the principles outlined in the Declaration of 
Helsinki.(18) The BRIGHT study’s goal was to assess variability related to various health 
behaviours among heart transplant patients internationally, to assess multilevel risk factors 
for medication non-adherence and to map and compare practice patterns among heart Tx 
centres with regard to chronic illness management. Therefore the BRIGHT study used 
different questionnaires (BRIGHT patient self-report questionnaire, BRIGHT patient 
interview questionnaire, BRIGHT clinicians’ self-report questionnaire, BRIGHT heart 
transplant director questionnaire and BRIGHT medical data extraction sheet) to assess the 
variables of interest. This substudy uses data collected through the BRIGHT clinicians’ self-
report questionnaire in which practice patterns regarding adherence assessment and 
adherence intervention strategies were assessed among other variables. 
Data were collected from March 2012 to October 2015. Details of the BRIGHT study’s 
methodology have been reported elsewhere.(17) Using a multistage sampling approach, the 
BRIGHT study included a convenience sample of 11 countries (Belgium, France, Germany, 
Italy, Spain, Switzerland, UK, Australia, Canada, USA and Brazil), a convenience sample of 36 
heart Tx centres (minimum two centres per country) and 100 clinicians practising in these 
heart Tx centres (one to five per centre). Inclusion criteria for heart Tx centres were the 
following: 50 or more heart Tx performed in the one to five years prior to inclusion, a location 
in one of the selected countries, and a formal letter of support signed by the centre’s transplant 
director and responsible administrator. The eligibility criteria for clinicians were the following: 
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over six months’ experience in their heart Tx centre; employment of 50% or greater in direct 
clinical practice; and familiarity with their centre’s post-Tx outpatient care. In cases when, 
based on these selection criteria, more than five clinicians were available, five were selected 
using a random sampling procedure. When fewer than five were available, all eligible clinicians 
were included. The BRIGHT study was approved by every participating transplant centre’s 
local ethics committee. 
Variables and measurement 
Characteristics of the heart transplant centres were reported by the transplant 
directors, using an investigator-developed instrument. The following variables were reported: 
type of centre (university teaching hospital, regional or community hospital, other); total 
number of heart Tx performed at the centre in the 12 months prior to enrolment in the BRIGHT 
study (2011); mean length of inpatient stay (in days) immediately after heart Tx; and total 
number of included heart Tx recipients in follow-up at the first data collection point more than 
one year post-Tx. 
Demographics of clinicians were provided directly by the clinicians, including 
information on nine variables: age in years; gender; current position in an heart Tx programme 
(transplant coordinator, staff nurse, advanced practice nurse, cardiologist); total years 
practising; years practising in heart Tx; years practising in current heart Tx programme; 
percentage of work spent in heart Tx care; primary workplace area (inpatient Tx unit, 
outpatient Tx unit, inpatient, and outpatient Tx unit); and completion of a certification 
programme in transplantation care (yes/no). 
Practice patterns with regard to adherence assessment and adherence intervention 
strategies were assessed via a questionnaire developed by Berben et al.(12) and completed by 
the participating transplant clinicians. This questionnaire was developed based on state-of-the 
art literature.(19–23) Content validity had been established in a group of expert clinicians 
working in organ Tx centres in the USA and the UK.(12) The questionnaire has already been 
used in different transplant populations.(12–14) Medication adherence was assessed using 
three methods: (a) questioning patients about medication adherence; (b) screening patients 
for risk factors for non-adherence (e.g. forgetfulness, busy lifestyle, complex treatment, etc.); 
and (c) using an electronic monitoring device to assess medication adherence. Furthermore, 
the questionnaire included a total of 24 items to assess adherence-enhancing interventions 
implemented and used in daily transplant practice (yes/no) at four time points along the 
transplant continuum: pre-Tx; during hospitalisation following transplant surgery; less than 
one year post-Tx; and one or more year post-Tx. Six items assessed educational/cognitive 
interventions; 10 measured counselling/behavioural interventions; and eight assessed 
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psychosocial/affective interventions. Clinicians were asked to indicate (yes/no) which of the 
adherence assessment methods and strategies their Tx programmes used. 
As several clinicians per centre could report on practice patterns, we aggregated the 
clinicians’ information at the transplant centre level. We scored an assessment or intervention 
as ‘present’ if all clinicians from one centre congruently responded ‘yes’ on the associated item. 
In cases in which all clinicians reported that an intervention was not used in their transplant 
centre, we scored this item as ‘absent’. When incongruences occurred between clinicians’ 
responses, we scored ‘incongruence in reporting intervention’. 
Data analysis 
We used descriptive statistics (frequencies, percentages, means/standard deviations 
and medians/interquartile ranges (IQRs)) as appropriate, based on measurement levels and 
distributions, to describe centre and clinician characteristics. Aggregated practice pattern data 
were summarised at the centre level for the three answer categories (present, absent, or 
incongruence in reporting intervention). 
As fewer than 10% of responses were missing, no data imputation was performed. 
Missing responses per category are reported in figures 6.1–6.5. Statistical analyses were 
performed using SPSS 23 (IBM SPSS Inc., Armonk, NY. USA).  
Results 
Sample characteristics 
Characteristics of participating Tx centres and transplant clinicians are shown in 
tables 6.1 and 6.2, respectively. A median of 20.0 (IQR 18.0, range 4–87) transplant 
procedures were performed per year, with a median of 325 (IQR 289.5, range 27–1500) heart 
Tx recipients with a post-transplant status of more than one year in follow-up in the respective 
heart Tx centre (table 6.1). Most clinicians (N=87, 87.0%) were women, with a mean age of 
45.9 years (SD 10.2); their most common position title was transplant coordinator (n=42, 
42.0%) (table 6.2). 
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Table 6.1: Characteristics of participating heart transplant centres 
Variable           N = 36 
Type of a transplant centre, n (%) 
 University teaching hospital      30 (83.3) 
 Regional or community hospital      4 (11.1) 
 Othera          2 (5.6) 
Total number of heart transplantations performed at a centre during past year (in 2011)1 
 Median (IQR)                   20.0 (18.0) 
Range          4 - 87 
Length of stay after a heart transplant in the hospital at a centre (in days)  
 Median (IQR)                    21.0 (10.7) 
Range          9- 38  
Total number of heart transplant recipients > 1 year post-transplant in follow-up2  
 Median (IQR)                   325 (289.5) 
 Range          27- 1500 
1 missing n=2, 2missing n=2; IQR: interquartile range; SD: standard deviation 
aOther types of centres including: one private & teaching non- profit hospital, one 
philanthropic institution 
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Table 6.2: Clinicians’ characteristics 
Variable         N = 100 
Age (years) 1  
Mean ± SD         45.9 ± 10.2 
Gender, n (%) 
Female         87 (87.0) 
Current position in a transplant program, n (%) 
Transplant Coordinator       42 (42.0) 
Staff nurse         39 (39.0) 
Advanced Practice Nurse       16 (16.0) 
Cardiologist         3 (3.0) 
Years practicing 
Median (IQR)         22.0 (18.0) 
Years practicing in heart transplantation2 
Median (IQR)         11.0 (13.0) 
Years practicing in the a current heart transplant program3 
Median (IQR)         8.0 (10.0) 
Percentage of work in heart transplant care4 
Mean ± SD         81.0 ± 26.9  
Median (IQR)         100 (50.0) 
Range          10- 100 
Primary workplace, n (%) 
Outpatient transplant unit       48 (48.0) 
Inpatient and outpatient transplant unit     37 (37.0) 
Inpatient transplant unit       10 (10.0) 
Other a          5 (5.0) 
Certification in transplantation 
Yes, n (%)         15 (15.0) 
1missing n=2; 2 missing n=1; 3missing n=2; 4missing n=2; IQR: interquartile range; SD: 
standard deviation 
aPrimary workplaces including: cardiomyopathy unit, outpatient transplant unit and day 
hospital, critical care unit (ICU) 
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Practice patterns regarding adherence assessment methods 
Figure 6.1 shows practice patterns related to adherence assessment methods. Across 
the entire transplant continuum, the most commonly used assessment method was 
questioning patients about medication adherence, with 75% of heart Tx centres using it pre-Tx 
and 88.9% using it in the first year post-Tx. Screening for risk factors ranged from 69.4% pre-
Tx to 83.3% in the first year post-Tx. The least popular assessment method, electronic 
monitoring, was used by only 2.8% of centres, and only in the first year post-Tx. 
 
Practice patterns regarding adherence intervention strategies 
All three types of the assessed intervention strategies (educational/cognitive, 
counselling/behavioural and psychosocial/affective) were applied to varying degrees both pre 
and post-transplant. The numbers and types of strategies applied varied considerably both 
between centres and across time periods (figures 6.2 - 6.5). 
Pre-transplant practice patterns, involving family or support persons in education and 
establishing partnerships with patients and their significant others, were used in 91.4% of 
transplant centres, followed by providing reading materials (82.9%), providing individual 
Figure 6.1:  Adherence assessment methods used at 4 time periods from pre- to > 1 year post-
transplant (N=36) 
MA = medication adherence, MNA = medication non-adherence 
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instruction (77.1%) and providing instruction regarding medication intake (68.6%) (figure 
6.2). Counselling–behavioural strategies were less frequently used pre-Tx. For this period, the 
most commonly applied strategy was training patients regarding medication intake (57.1%) 
(figure 6.2). 
Post-transplant practice patterns mainly resembled those reported pre-transplant. The 
only exception was training patients regarding medication intake during inpatient recovery, 
which was used by 100% of the included centres (figures 6.2 and 6.5). Still, adherence 
reminders during clinical visits (a counselling/behavioural strategy) were used more 
frequently post-transplant (67.6–74.3%) (figure 6.4) than pre-transplant (57.1%) (figure 
6.2). 
Use of computer-assisted educational programmes varied from 8.3% (pre-Tx and 
during hospitalisation after transplant surgery) to 2.9% (during the first year post-Tx). While 
video tutorials were the most used educational/cognitive intervention pre-transplant (17.1%), 
fewer than 5% of centres reported using them at other post-transplant time points (2.9–8.3%) 
(figures 6.2 and 6.3). Across the Tx continuum, the use of electronic monitoring devices was 
rare (2.9–5.7%) (figures 6.2 and 6.4). 
Importantly, examining the evolution of the most commonly applied strategies over 
time, decreases were observed in most interventions beyond the first year post-transplant 
(figures 6.3–6.5). There were three exceptions: reducing the complexity of the medication 
regimen (which rose from 45.7% to 57.1%) (figures 6.2 and 6.4), using motivational 
interviewing (which increased slightly from 25.7% to 28.6%) (figure 6.5) and establishing 
case management services (which remained stable at 22.9%) (figure 6.5). 
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Figure 6.2: Percentages of applied medication adherence intervention strategies in heart 
transplant centres pre-transplant (N=36) 
Figure 6.3: Percentages of educational/cognitive intervention strategies in heart transplant 
centres post-transplant (N=36) 
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Figure 6.4:  Percentages of applied counselling/behavioural intervention in heart transplant 
centres post- transplant (N=36) 
Figure 6.5:  Percentages of applied psychosocial/affective intervention strategies in heart transplant 
centers post-transplant (N=36) 
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Discussion 
The International Society for Heart and Lung Transplantation (ISHLT) consensus 
statement(11) calls for the integration of adherence assessment and management into heart 
transplant care. Using a sample of 36 heart transplant centres in 11 countries on four 
continents, the present study is the first to provide such extensive information on practice 
patterns of medication adherence assessment and medication adherence strategies along the 
transplant continuum. To our knowledge, its data source, the BRIGHT study, is the largest ever 
systematically to map practice patterns regarding adherence assessment and interventions in 
solid organ transplantation(13) as well as in other chronic diseases.(24, 25) Our findings 
highlight the fact that, with some variability between intervention types and phases, a growing 
number of transplant centres have integrated medication adherence assessment and 
interventions into regular care along the transplant continuum. Compared to earlier studies 
addressing healthcare professionals working in different transplant programmes,(12, 13, 26) 
we observed a trend in more implemented adherence-enhancing interventions. ISHLT 
guidelines and increased awareness of the importance of medication adherence in 
transplantation very likely encouraged investment in assessing this risk factor for poor post-
Tx outcomes.(11) 
According to our findings, questioning patients about medication adherence via self-
report was the most commonly applied assessment method. This finding is similar to those of 
earlier European studies in cardiovascular(12) and transplant patients.(13, 14) In clinical 
practice, patient self-report is an easily implemented approach that allows quick, economical 
assessment of medication adherence.(27) However, used alone, self-reporting commonly 
underestimates patients’ non-adherence;(27) therefore, to increase its sensitivity, a 
combination of assessment strategies is recommended.(28) Furthermore, in line with a recent 
Institute of Medicine report regarding the handling of psychosocial and behavioural data, 
adherence information should also be integrated into the patient’s electronic medical 
record.(29) 
Although the significance of non-adherence to immunosuppressive medication has 
been acknowledged by the healthcare transplant community for many years, our data indicate 
that few adherence interventions are applied consistently. Many more are used mainly during 
specific phases of the transplant continuum.(16) Contradicting previous smaller studies 
applying the same methodology after solid organ transplantation,(13) after stem cell 
transplantation,(14) and in cardiovascular care,(12) we found that the prevalence of 
educational/cognitive interventions (e.g. providing self-care reading materials, printed 
medication instructions, or individual teaching) has declined. Current findings show the use 
of more varied adherence interventions in heart transplant care, the most common of which 
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use counselling/behavioural strategies, e.g. training patients during their inpatient recovery to 
take their medications properly at home, or teaching patients to use cueing. 
Psychosocial/affective strategies (e.g. involving family or other support persons in educational 
and behavioural interventions, others) are also integrated, but to a lesser extent. 
Still, while certain adherence-enhancing strategies are clearly more effective than 
others, the most useful are not the most frequently used. Meta-analyses and systematic reviews 
focusing on the efficacy of adherence-enhancing interventions indicate that succinct written 
instructions, packaging interventions, electronic reminders (e.g. via text messaging), and 
simplification of the medication regimen are most efficacious to improve patients’ long-term 
medication adherence.(30, 31) Recently published randomised controlled studies in 
transplantation also highlight the value of electronic monitoring feedback(32) and behavioural 
contracts.(33) However, the most recent meta-analysis examining the efficacy of adherence-
enhancing intervention strategies suggests that complex interventions involving multiple 
components tailored towards the patient’s needs improve medication adherence most 
effectively.(34) This necessitates a comprehensive assessment of patients’ needs and potential 
barriers against an optimal medication adherence. Further research is needed to demonstrate 
whether the same strategies are also effective to maintain medication adherence. 
One key finding of our study is the observed decrease in the intensity of adherence 
interventions from the first year post-Tx to more than one year post-Tx. Given the reported 
correlation between increases in medication non-adherence and elapsed time post-
transplant,(5) this is particularly worrisome. The call for continuous life-long support of 
medication adherence might also be underlined by the recent findings of a qualitative interview 
study in 14 heart transplant recipients. The study clearly illustrated that uncertainty can be 
seen as a common state among heart transplant recipients. Many patients struggle to 
reorganise their self-structure and everyday life.(35) 
Continuous support can be delivered during clinical encounters; but to bridge the gaps 
between transplant centre visits, E-health approaches could also be used to maintain patient 
motivation through feedback and reminders.(36–38) However, our data indicate that, 
compared to direct patient contact, these strategies receive limited use as alternative delivery 
modes for adherence interventions. Our findings show that, in our sample, the adoption of 
more sophisticated methods (electronic monitoring, computer assisted learning, video) is 
limited. 
One barrier against integrating medication adherence interventions into clinical 
practice can be inadequate time and funding in clinical settings throughout the patient’s 
transplant journey.(19) For example, most healthcare systems do not reimburse patient 
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counselling as a part of the fee for service or capitation payment systems.(19) However, various 
capitation payment systems cover at least one year of care or outcome-related treatment, 
offering incentives for effective self-management support. Having proved effective, these 
systems provide guidance towards successful implementation and sustainability of adherence 
interventions in clinical practice.(39) Still, transplant clinicians need specific training to assess 
adherence and intervene when needed.(19) Current best clinical practice also includes chronic 
care models based on supporting patients’ self-management involving collaborative 
approaches between informed, activated patients and prepared, proactive healthcare 
teams.(40) Besides self-management support, this model focuses on continuity of care, 
partnership with families, decision-making support and the use of an elaborative clinical 
information system. Within this model, the healthcare provider is linked with community 
resources and policies, as well as the healthcare system. Research on the chronic care model 
has shown that the chronically ill, e.g. with asthma, have demonstrated improvement in 
medication adherence.(41) 
Limitations 
In assessing each centre’s practice patterns, we used clinician reports alone, i.e. no 
independent observations were executed to confirm that those reports reflected actual 
practice. Nevertheless, given the broad geographical coverage of the BRIGHT study’s data 
collection, no alternative approach was available to map practice patterns. While using various 
informants from each transplant centre, then combining the information later at the level of 
the centre is a strength, considerable incongruences were observed between answering 
patterns (range 5.6–40%). Therefore, we adopted a conservative approach in our analysis, 
reporting only interventions reported congruently as present. 
Also, continent or country-specific analyses were beyond the scope of this study. For 
future research, then, it might be useful to focus on potential geographical variations in 
practice patterns related to medication adherence assessment and strategies. 
While the use of an established instrument to assess practice patterns regarding applied 
assessment and intervention strategies allows comparison with previous research, this also has 
its limitations. Our categorisation of adherence strategies built on our group’s previous work 
assessing educational/cognitive, counselling/behavioural and psychosocial/affective 
strategies. Given the recent publication of the behaviour change technique taxonomy V1 of 
Michie et al.,(42) it would be useful to invest in instrument development to assess practice 
patterns congruent with this taxonomy. 
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Like the taxonomy of Michie et al., our instrument includes only patient-level 
interventions. Further, given recent BRIGHT study insights that multilevel factors contribute 
to Tx medication non-adherence, calling for multilevel interventions – assessment of higher 
level interventions via an updated instrument (e.g. support systems for drug costs) is 
recommended.(43, 44) Also, it would be worthwhile to explore further the use of E- health 
applications in Tx adherence management. Here, patients’ individual factors should be 
considered, as they can influence the efficacy of adherence-enhancing interventions. For 
example, health literacy is a relevant factor to consider when rolling out adherence 
interventions.(45) Furthermore, future studies should aim at identifying underlying reasons 
that are responsible for existing gender differences in patient outcomes. As the recently 
published NEW HEART study (2017) has shown that women are more likely to experience 
moderate or severe allograft rejection and to be hospitalised for acute rejection than men, 
gender aspects should be carefully examined in ongoing cardiovascular adherence 
research.(46) 
Conclusion 
Various educational/cognitive, counselling/behavioural and psychosocial/affective 
adherence-enhancing intervention strategies are implemented along the transplant 
continuum. However, although non-adherence is known to increase with time, we 
demonstrated that the application of adherence interventions decreases in the longer term 
post-transplant. Transplant follow-up care should integrate support for adherence beyond the 
first year post-transplant when the risk of non-adherence is increasing. 
Implications for practice 
• Contrary to the current practice of many transplant centres, adherence assessment and 
intervention strategies should be implemented across the entire transplantation 
continuum, and not only early after transplantation, as it is known that non-adherence 
continues to increase over time post-transplant. 
• Recent systematic literature reviews and meta-analyses indicate the value of tailored 
multi-component adherence interventions (e.g. electronic monitoring feedback, 
behavioural contracts, succinct written instructions, packaging interventions, technically 
based reminders and simplification of medication regimens). 
• E-health technologies are rarely implemented in heart transplant centres, although they 
can be used to deliver adherence interventions, especially to circumvent the lack of 
resources to organise long-term follow up. 
• Clinicians should be trained to provide sustainable adherence assessment and 
intervention strategies across the entire transplantation continuum to prevent non-
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adherence long-term post-transplant (e.g. methods of strengthening self-management of 
patients). In particular, training should include the facilitation of new health 
technologies. 
• Providing self-management support in the clinical setting should be strongly backed in the 
healthcare system through adequate time resources and funding. 
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The international prevalence and variability of nonadherence 
to the nonpharmacologic treatment regimen after heart 
transplantation: findings from the cross-sectional BRIGHT 
study 
 
Abstract 
Introduction: Heart transplant (HTx) recipients need to follow a complex therapeutic 
regimen. We assessed the international prevalence and variability in non-adherence to six non-
pharmacologic treatment components (physical activity, sun protection, diet, alcohol use, non-
smoking, and outpatient follow-up visits). 
Methods: We used self-report data of 1397 adult HTx recipients from the 36-HTx-center, 11-
country, 4-continent, cross-sectional BRIGHT study (ClinicalTrials.gov ID: NCT01608477). 
The non-adherence definitions used were: Physical activity: <3 times/week 20 minutes’ 
vigorous activity, <5 times/week 30 minutes’ moderate activity, or <5 times/week a 
combination of either intensity; Sun protection: not “always” applying any sun protection; 
Diet: not “often” or “always” following recommended diet(s); Alcohol use: > 1 alcoholic 
drink/day (women) or > 2 drinks/day (men); Smoking: current smokers or stopped <1 year 
before; Follow-up visits: missing ≥1 of the last 5 outpatient follow-up visits. Overall prevalence 
figures were adjusted to avoid over- or underrepresentation of countries. Between-country 
variability was assessed within each treatment component via chi-square testing. 
Results: The adjusted study-wide non-adherence prevalence figures were: 47.8% for physical 
activity (95% CI [45.2-50.5%]), 39.9% for sun protection (95% CI [37.3-42.5%]), 38.2% for diet 
recommendations (95% CI [35.1-41.3%]), 22.9% for alcohol consumption (95% CI [20.8%-
25.1%]), 7.4% for smoking cessation (95% CI [6.1%-8.7%]), and 5.7% for follow-up visits (95% 
CI [4.6-6.9%]). Significant variability was observed between countries in all treatment 
components except follow-up visits. 
Conclusion: Non-adherence to the post-HTx non-pharmacologic treatment regimen is 
prevalent and shows significant variability internationally, suggesting a need for tailored 
adherence-enhancing interventions. 
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Introduction 
Evidence shows that long-term graft attrition rates after adult heart transplantation 
(HTx) have not changed markedly over time, and that reduced mortality rates are almost 
exclusively attributable to survival gains in the early post-HTx phase (1, 2). Improving long-
term survival is therefore a priority in research and clinical practice. Nevertheless, 
immunosuppressant intake might hamper long-term survival (3). Indeed, long-term 
immunosuppressant intake may trigger systemic and metabolic complications and elevate the 
risk of cancer, augmenting the risk of graft injury and all-cause mortality. According to the 
most recent registry data (4), at 5 years post-HTx, 51.1% of HTx recipients have renal 
dysfunction, 35.5% have diabetes, 29.3% have cardiac allograft vasculopathy, and 15.9% have 
malignancy (all types combined). 
To prevent or delay the incidence of these co-morbidities, post-HTx care guidelines (5) 
recommend lifelong follow-up to monitor graft function and lifestyle modifications including 
weight control, physical activity, diet (e.g., low fat and sodium intake), abstinence from 
smoking or heavy alcohol intake, and use of sun protection. It remains unclear, however, to 
what extent HTx recipients are able to follow this complex therapeutic regimen. The bulk of 
evidence on post-HTx behavior focuses on medication adherence; robust evidence on the 
prevalence of non-adherence to the post-HTx non-pharmacologic therapeutic regimen is 
scarce. 
A 2007 meta-analysis (6) showed non-adherence rates of 33.7 cases per 100 patient-
years for physical activity, 28.1 cases for following a diet, 8.5 cases for attending clinic 
appointments, 4.9 cases for alcohol use, and 3.2 cases for tobacco use in HTx recipients. 
However, these estimates were based on a small number of available studies. Moreover, 
although meta-analyses pool and summarize evidence, non-adherence prevalence rates for 
each behavior might vary widely across studies due to methodological issues, e.g., non-
standard measurement methods or sampling strategies. Since that 2007 meta-analysis, the few 
related studies published have most commonly used small samples or focused on a single 
behavior. Larger studies investigating multiple behaviors enrolled patients from one center 
only (6, 7), providing no evidence on variations in HTx recipients’ health behaviors between 
centers or countries. Physical inactivity in the general population, for instance, is far more 
prevalent in Belgium, Spain and the UK than in the Netherlands, Germany or France (8), and 
tobacco smoking is more prevalent in Europe than in the Americas (9). Generating and 
comparing regional non-adherence rates could help HTx centers prioritize lifestyle 
interventions and plan resources to remedy problems specific to their local populations. 
Therefore, the international HTx community would benefit from a single large study using a 
homogeneous methodological approach to investigate the prevalence of non-adherence to all 
post-HTx non-pharmacologic treatment components. 
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Therefore, this study has two aims: (1) to describe the prevalence of non-adherence to 
the post-HTx non-pharmacologic treatment regimen (i.e. physical activity, sun protection, diet 
recommendations, limiting alcohol use, smoking abstinence, and appointment keeping); and 
(2) to describe between-country variability in non-adherence rates regarding these health 
behaviors and test its significance in a large sample of adult HTx recipients from various 
countries. 
Patients and methods 
This study used data from the Building Research Initiative Group: Chronic Illness 
Management and Adherence in Transplantation (BRIGHT) study (10, 11) (ClinicalTrials.gov 
ID: NCT01608477), a cross-sectional study assessing healthcare providers’ practice patterns 
and the prevalence and variability of non-adherence to the post-HTx treatment regimen in 36 
HTx centers from 11 countries in Asia, Europe, North and South America. 
Sampling and data collection 
The BRIGHT study used a multistage sampling approach. Countries and HTx centers 
were included via convenience sampling, enrolling at least 2 centers per country. HTx centers 
were eligible to participate in the study if they met all of the following criteria: 
1. performance of at least 50 HTx over the 60 months prior to inclusion 
2. location in Europe, North America, South America, or Australia 
3. willingness to provide formal study support through the center’s HTx director and 
responsible administrator. 
Using a stratified random sampling approach based on center size (10), HTx recipients were 
eligible to participate if they: 
1. were adults (≥ 18 years at time of enrolment); 
2. were transplanted and followed up for routine care at a participating HTx center; 
3. received their HTx as a single-organ transplant; 
4. underwent a first-time HTx (no re-transplantation); 
5. were 1–5 years post-HTx; 
6. were able to read and understand one of the study languages; and 
7. were willing to provide written informed consent. 
HTx recipients were excluded if they had participated in adherence intervention 
research or drug trials during the 6 months prior to inclusion or if they had received 
professional support for medication intake. Detailed information on the methodology of the 
BRIGHT study is reported elsewhere (10, 11). 
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The data were collected (once for each HTx recipient) between March 2012 and October 
2015 after obtaining ethical approval from each participating center’s institutional review 
board (IRB) or ethics committee. 
Variables and measurement 
To describe the sample, socio-demographic characteristics were collected via patient 
interviews during a scheduled clinic visit (i.e., age, gender, marital status, ethnicity, 
educational level, employment status). Clinical data (date of HTx and heart failure etiology) 
were captured based on chart reviews. 
Non-adherence to 6 components of the non-pharmacologic treatment regimen (i.e., 
physical activity, non-smoking status, limited alcohol use, use of sun protection measures, 
following of diet recommendations, and the keeping of follow-up appointments) was assessed 
by a self-report questionnaire during a scheduled outpatient clinic visit (12-16). Table 7.1 
describes how each component was measured and scored.
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Table 7.1: Self-report instruments used to measure the investigated health behaviors 
Variable Instrument 
• Number of items 
• Recall period 
• Response options 
• Non-adherence definitions 
Validity/Reliability 
Physical activity 
(PA) 
Brief Physical 
Activity 
Assessment tool 
(12) 
• 2 items 
• Average week 
• No. times/week 20 min. of vigorous PA: <1 time/week / 1-2 times/week / ≥3 times/week 
& 
No. times/week 30 min. of moderate PA: <1 time/week / 1-2 times/week / 3-4 times/week / ≥5 time/week 
• Non-adherence: <3 times/week vigorous PA OR <5 times/week moderate PA OR <5 times/week a 
combination of either PA intensities 
Assessed against an 
accelerometer: 
- criterion validity 
(10) (ĸ= 0.40, 95% CI= 
0.12-0.69) 
- inter-rater 
reliability (10) (ĸ= 
0.53, 95% CI= 0.33-
0.72) 
Smoking status 
1 item from the 
Swiss Health 
Survey (13) 
• 1 item 
• 1 year 
• Currently smoking / Stopped smoking less than a year before / Stopped smoking more than a year before / 
Never smoked 
• Non-adherent: currently smoking or stopped less than a year before 
No available 
information on 
psychometric 
properties 
Alcohol use 
Investigator 
developed (14) 
• 3 items 
• Average week 
• Yes / No; 
No. shots or glasses/week (1.5 oz. = 45 ml); 
No. pints of beer/week (1 pint = 12oz. = 355 ml); 
No. glasses of wine/week (1 glass = 5 oz. = 148 ml) 
No. times drinking/week: Daily / 3-4 times/week / 1-2 times/month / <1 time/month / Never 
• Non-adherent = heavy drinker: > 1 drink/day (women); > 2 drinks/day (men) 
No available 
information on 
psychometric 
properties 
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Variable Instrument 
• Number of items 
• Recall period 
• Response options 
• Non-adherence definitions 
Validity/Reliability 
Sun protection 
Swiss study on 
health of people 
with cancer, 
leukemia, tumor 
in childhood 
(15) 
and 
Cambridge 
University 
Hospitals' 
perception of 
skin cancer in 
transplant 
recipients scale 
(16) 
• 4 items 
• Current situation 
• Using sunscreen, wearing protective clothing, staying in the shade, being sensitive to the time of the day: 5-
point Likert scale ranging from ‘1= never’ to ‘5= always' 
• Non-adherent: not always using at least 1 of these sun protection methods 
Unidimensional scale, 
having a Cronbach’s 
alpha of 0.59 
Diet 
recommendations 
Investigator 
developed 
• 5 items 
• 1 year 
• Yes/No for advice to follow a specific diet (low salt, low calorie, low saturated fats, low sugar, or other 
diets) and, correspondingly, a 5-point Likert scale ranging from ‘1= never to ‘5= always' to evaluate 
adherence to each recommended diet. 
• Non-adherent: score 1-3 on any of the 5 diets recommended by the transplant team 
No available 
information on 
psychometric 
properties 
Follow-up 
appointment 
keeping 
Investigator 
developed 
• 1 item 
• Previous 5 scheduled clinic appointments 
• No. appointments missed: 6-point scale ranging from ‘none’ to ‘6= all 5 appointments’ 
• Non-adherent: missed ≥ 1 appointment 
No available 
information on 
psychometric 
properties 
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Statistical analysis 
Frequencies and percentages (for categorical variables) or measures of central 
tendency and dispersion (for continuous variables) are used to describe the sample. The data 
were aggregated on the country level and the level of the entire sample as appropriate. The 
prevalence of non-adherence to each of the non-pharmacologic treatment components is 
presented as a percentage. To avoid over- or underrepresentation of any country’s HTx 
recipient population, the overall non-adherence prevalence for each treatment component was 
calculated as a weighted average. This was accomplished by multiplying each country’s non-
adherence rate by a weighting factor that corresponds to the ratio of the HTx recipient 
population in the corresponding country to that of all included countries in the time period 
corresponding to that of the study’s data collection in the country. 
Standard deviations and ranges are used to describe between-country variability in 
non-adherence prevalence. Chi-square testing was used to determine the significance of this 
variability. After applying the Bonferroni correction to the significance level of p< 0.05 to 
account for multiple testing, the significance level was set at 0.008. 
With one exception–alcohol use–missing data affected fewer than 10% of the cases 
involving the variables used to calculate non-adherence to the investigated health behaviors. 
Accordingly, patients with completely missing data on a health behavior of interest were 
excluded only from the corresponding analysis (available-case analysis). For alcohol use, 
missing data in the 2 variables, i.e., number of drinks/week and weekly drinking frequency, 
were imputed using the R (version 3.4.2) programming language and the MICE (Multivariate 
Imputation by Chained Equations) package. For all other analyses, Stata® 15 (StataCorp LLC, 
Texas, USA) was used. 
Results 
Sample characteristics 
At the 36 participating centers, of 2523 HTx recipients found eligible for inclusion, 1677 
were randomly selected and invited to participate. Of this number, 244 declined and 36 died 
before enrolment, resulting in a final sample size of 1397 HTx recipients. Information on the 
sample size per country and health behavior is presented in table 7.2. 
Table 7.3 shows the main characteristics of the final HTx recipient sample, overall and 
per country. Participants were 72.7% (1011) male, and on average 53.7 (SD: 13.2) years old and 
3.4 (SD: 1.4) years post-HTx at time of enrollment. 
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Table 7.2: Number of heart transplant recipients with data on each of the investigated behaviors (per country and per health behavior) 
 
Appointment 
keeping 
Smoking 
cessation 
Alcohol 
use 
Diet 
recommendations 
Sun 
protection 
Physical 
activity 
Belgium (n=74) 74 74 74 48 70 74 
France (n=160) 157 157 160 110 150 146 
Germany (n=67) 65 64 67 19 62 65 
Italy (n=111) 111 110 111 64 110 105 
Spain (n=227) 224 221 227 218 220 222 
Switzerland (n=47) 46 46 47 14 44 46 
United Kingdom (n=99) 99 99 98 28 98 96 
Canada (n=121) 116 115 120 88 116 116 
USA (n=340) 336 335 339 278 334 334 
Australia (n=51) 51 51 51 26 51 51 
Brazil (n=100) 97 97 100 71 94 85 
Total sample (N=1397) 1376 1369 1394 964* 1349 1340 
Missing data 21 28 3 81 48 57 
*352 HTx recipients reported not having been recommended any diet 
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Table 7.3: Sociodemographic and clinical characteristics of the participating heart transplant recipients  
 Overall 
N=1397 
Europe 
n=785 
North America 
n=461 
Australia 
n=51 
South 
America 
n=100 
Belgium 
n=74 
France 
n=160 
Germany 
n=67 
Italy 
n=111 
Spain 
n=227 
Switzerland 
n=47 
UK 
n=99 
Canada 
n=121 
USA 
n=340 
Australia 
n=51 
Brazil 
n=100 
Age, years (n) 
Mean (SD) 
1380 
53.7 (13.2) 
74 
53.3 (12.6) 
160 
50.2 (13.0) 
65 
55.3 (10.3) 
111 
56.7 (12.5) 
227 
56.5 (11.7) 
47 
50.1 (14.6) 
98 
49.3 (14.8) 
113 
55 (13.4) 
335 
56.3 (12.8) 
51 
49.7 (14.2) 
99 
46.8 (13.3) 
Gender (n) 
Male, n (%) 
1390 
1011 (72.7%) 
74 
50 (67.6%) 
160 
121 (75.6%) 
65 
50 (76.9%) 
111 
93 (83.8%) 
227 
174 (76.7%) 
47 
32 (68.1%) 
98 
76 (77.6%) 
120 
87 (72.5%) 
337 
229 (68%) 
51 
31 (60.8%) 
100 
68 (68%) 
Ethnicity (n) 
Caucasian, n (%) 
1381 
1186 (85.9%) 
74 
73 (98.7%) 
159 
142 (89.3%) 
65 
65 (100%) 
111 
110 (99.1%) 
224 
205 (91.5%) 
47 
43 (91.5%) 
99 
93 (93.9%) 
119 
106 (89.1%) 
336 
251 (74.7%) 
47 
33 (70.2%) 
100 
65 (65%) 
Education (n) 
Primary school, n (%) 
Secondary school, n (%) 
Further education, n (%) 
University, n (%) 
1377 
187 (13.6%) 
426 (30.9%) 
294 (21.4%) 
470 (34.1%) 
73 
3 (4.1%) 
42 (57.5%) 
15 (20.6%) 
13 (17.8%) 
158 
10 (6.3%) 
53 (33.5%) 
64 (40.5%) 
31 (19.6%) 
65 
7 (10.8%) 
6 (9.2%) 
40 (61.5%) 
12 (18.5%) 
111 
37 (33.3%) 
51 (46%) 
2 (1.8%) 
21 (18.9%) 
220 
94 (42.7%) 
60 (27.3%) 
25 (11.4%) 
41 (18.6%) 
47 
5 (10.6%) 
3 (6.4%) 
32 (68.1%) 
7 (14.9%) 
99 
0 
45 (45.5%) 
24 (24.2) 
30 (30.3%) 
119 
3 (2.4%) 
35 (29.4%) 
16 (13.5%) 
65 (54.6%) 
339 
3 (0.9%) 
71 (20.9%) 
59 (17.4%) 
206 
(60.8%) 
50 
0 
9 (18%) 
17 (34%) 
24 (48%) 
96 
25 (26%) 
51 (53.1%) 
0 
20 (20.8%) 
Employment status (n) 
Employed, n (%) 
1391 
413 (29.7%) 
74 
18 (24.3%) 
160 
58 (36.3%) 
65 
17 (26.2%) 
111 
33 (29.7%) 
226 
27 (12%) 
47 
20 (42.6%) 
99 
37 (37.4%) 
119 
39 (32.8%) 
339 
117 (34.5%) 
51 
25 (49%) 
100 
22 (22%) 
Marital status (n) 
Single, n (%) 
Married/cohabiting, n (%) 
Divorced/separated, n (%) 
Widowed, n (%) 
1387 
242 (17.5%) 
955 (68.9%) 
149 (10.7%) 
41 (3%) 
74 
8 (10.8%) 
56 (75.7%) 
8 (10.8%) 
2 (2.7%) 
159 
36 (22.6%) 
103 (64.8%) 
19 (12%) 
1 (0.6%) 
65 
8 (12.3%) 
49 (75.4%) 
6 (9.2%) 
2 (3.1%) 
110 
14 (12.7%) 
83 (75.5%) 
11 (10%) 
2 (1.8%) 
227 
26 (11.5%) 
158 (69.6%) 
33 (14.5%) 
10 (4.4%) 
47 
8 (17%) 
32 (68.1%) 
6 (12.8%) 
1 (2.1%) 
97 
26 (26.8%) 
59 (60.8%) 
10 (10.3%) 
2 (2.1%) 
120 
19 (15.8%) 
82 (68.3%) 
11 (9.2%) 
8 (6.7%) 
337 
60 (17.8%) 
234 (69.4%) 
30 (8.9%) 
13 (3.9%) 
51 
13 (25.5%) 
34 (66.7%) 
4 (7.8%) 
0 
100 
24 (24%) 
65 (65%) 
11 (11%) 
0 
Time post-HTx (n) 1395 74 160 67 111 227 47 99 121 340 49 100 
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 Overall 
N=1397 
Europe 
n=785 
North America 
n=461 
Australia 
n=51 
South 
America 
n=100 
Belgium 
n=74 
France 
n=160 
Germany 
n=67 
Italy 
n=111 
Spain 
n=227 
Switzerland 
n=47 
UK 
n=99 
Canada 
n=121 
USA 
n=340 
Australia 
n=51 
Brazil 
n=100 
Years, Mean (SD) 3.4 (1.4) 3.4 (1.2) 3.6 (1.3) 3.4 (1.4) 3.2 (1.3) 3.6 (1.3) 3.5 (1.2) 3.5 (1.2) 3.7 (1.4) 3 (1.3) 4.2 (1.3) 2.8 (1.5) 
Heart failure etiology (n) 
Idiopathic 
Ischemic 
Valvular 
Congenital 
Other 
1362 
714 (52.4%) 
401 (29.4%) 
44 (3.2%) 
45 (3.3%) 
158 (11.6%) 
74 
33 (44.6%) 
28 (37.8%) 
2 (2.7%) 
2 (2.7%) 
9 (12.2%) 
159 
88 (55.4%) 
44 (27.7%) 
10 (6.3%) 
5 (3.1%) 
12 (7.6%) 
65 
33 (50.8%) 
23 (35.4%) 
0 
1 (1.5%) 
8 (12.3%) 
111 
69 (62.2%) 
31 (27.9%) 
3 (2.7%) 
3 (2.7%) 
5 (4.5%) 
226 
130 (57.5%) 
64 (28.3%) 
15 (6.6%) 
6 (2.7%) 
11 (4.9%) 
47 
31 (66%) 
8 (17%) 
3 (6.4%) 
2 (4.3%) 
3 (6.4%) 
93 
55 (59.1%) 
18 (19.4%) 
1 (1.1%) 
14 (15.1%) 
5 (5.4%) 
118 
68 (57.6%) 
35 (29.7%) 
1 (0.9%) 
5 (4.2%) 
9 (7.7%) 
328 
144 (43.9%) 
128 (39%) 
4 (1.2%) 
4 (1.2%) 
48 (14.6%) 
48 
31 (64.6%) 
11 (22.9%) 
1 (2.1%) 
2 (4.2%) 
3 (6.3%) 
93 
32 (34.4%) 
11 (11.8%) 
4 (4.3%) 
1 (1.1%) 
45 (48.4%) 
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Overall prevalence of non-adherence to the non-pharmacologic treatment 
regimen 
Figure 7.1 shows the overall unadjusted and adjusted prevalence of non-adherence to 
the different non-pharmacologic treatment components. Based on the adjusted values, the 
highest prevalence of non-adherence was observed for physical activity: 47.8% (95% CI 
[45.2%-50.5%]) of the sample were insufficiently physically active. Sun protection followed, 
with 39.9% (95% CI [37.3%-42.5%]) not always protecting themselves as recommended. Of 
those who were advised to follow specific diets, 38.2% (95% CI [35.1%-41.3%]) did not always 
or often follow recommendations. Heavy alcohol use was reported by 22.9% (95% CI [20.8%-
25.1%]); 7.4% (95% CI [6.1%-8.7%]) were still smokers or had stopped less than one year prior 
to data collection. Appointment keeping had the lowest non-adherence prevalence, with 5.7% 
(95% CI [4.6%-6.9%]) missing at least one of their prior five outpatient clinic appointments. 
Between-country variability in non-adherence prevalence 
Figure 7.2 shows the between-country variability in the prevalence of non-adherence 
to each of the investigated health behaviors. The largest variability (SD: 13.6%) was observed 
in heavy alcohol use, which ranged from 2% in Brazil to 42.9% in the UK. This was followed by 
variability in non-adherence to sun protection (SD: 9.5%): 24.1% of Spanish HTx recipients 
did not always use sun protection as opposed to 51.4% in Belgium, which had the highest 
prevalence. Variability in insufficient physical activity (SD: 8.5%) came third, with Spain’s 
participants having the lowest rate (32%) and France’s the highest (59.6%). Diet non-
adherence came fourth (SD: 7.1%), varying from 26.6% (Spain) to 48.2% (USA). In Australia, 
no HTx recipients reported non-adherence to smoking cessation, while this number was 12.7% 
in France, with relatively low variability between countries (SD: 4%). Non-adherence to 
appointment keeping had the lowest variability (SD: 2.9%) ranging from 3% (UK) to 11.8% 
(Australia). 
Table 7.4 shows that the observed variability was statistically significant for all 
behaviors except appointment keeping. Figure 7.3 depicts each behavior’s non-adherence 
prevalence per country, indicating which behaviors are least and most problematic within each 
country.
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Figure 7.1: The adjusted and unadjusted overall prevalence of non-adherence to the non-pharmacologic treatment regimen 
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Figure 7.2: Behavior-wise investigation of the variability in non-adherence prevalence between countries 
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Table 7.4: Chi-square test results for the between-country variability within each health behavior (showing non-adherence rates) 
 
Appointment 
keeping 
Smoking cessation Alcohol use 
Diet 
recommendations 
Sun protection Physical activity 
Adherent 
Not 
adherent 
Adherent 
Not 
adherent 
Adherent 
Not 
adherent 
Adherent 
Not 
adherent 
Adherent 
Not 
adherent 
Adherent 
Not 
adherent 
Belgium 
70 
(94.6%) 
4 
(5.4%) 
65 
(87.8%) 
9 
(12.2%) 
44 
(59.5%) 
30 
(40.5%) 
29 
(60.4%) 
19 
(39.6%) 
34 
(48.6%) 
36 
(51.4%) 
36 
(48.6%) 
38 
(51.4%) 
France 
150 
(95.5%) 
7 
(4.5%) 
137 
(87.3%) 
20 
(12.7%) 
96 
(60%) 
64 
(40%) 
75 
(68.2%) 
35 
(31.8%) 
92 
(61.3%) 
58 
(38.7%) 
59 
(40.4%) 
87 
(59.6%) 
Germany 
60 
(92.3%) 
5 
(7.7%) 
59 
(92.2%) 
5 
(7.8%) 
52 
(77.6%) 
15 
(22.4%) 
10 
(52.6%) 
9 
(47.4%) 
34 
(54.8%) 
28 
(45.2%) 
33 
(50.8%) 
32 
(49.2%) 
Italy 
107 
(96.4%) 
4 
(3.6%) 
108 
(98.2%) 
2 
(1.8%) 
99 
(89.2%) 
12 
(10.8%) 
45 
(70.3%) 
19 
(29.7%) 
83 
(75.5%) 
27 
(24.5%) 
53 
(50.5%) 
52 
(49.5%) 
Spain 
217 
(96.9%) 
7 
(3.1%) 
205 
(92.8%) 
16 
(7.2%) 
202 
(89%) 
25 
(11%) 
160 
(73.4%) 
58 
(26.6%) 
167 
(75.9%) 
53 
(24.1%) 
151 
(68%) 
71 
(32%) 
Switzerland 
43 
(93.5%) 
3 
(6.5%) 
45 
(97.8%) 
1 
(2.2%) 
32 
(68.1%) 
15 
(31.9%) 
10 
(71.4%) 
4 
(28.6%) 
23 
(52.3%) 
21 
(47.7%) 
30 
(65.2%) 
16 
(34.8%) 
United 
Kingdom 
96 
(97%) 
3 
(3%) 
94 
(94.9%) 
5 
(5.1%) 
56 
(57.1%) 
42 
(42.9%) 
18 
(64.3%) 
10 
(35.7%) 
49 
(50%) 
49 
(50%) 
63 
(65.6%) 
33 
(34.4%) 
Canada 
107 
(92.2%) 
9 
(7.8%) 
104 
(90.4%) 
11 
(9.6%) 
92 
(76.7%) 
28 
(23.3%) 
54 
(61.4%) 
34 
(38.6%) 
61 
(52.6%) 
55 
(47.4%) 
70 
(60.3%) 
46 
(39.7%) 
USA 
324 
(96.4%) 
12 
(3.6%) 
318 
(94.9%) 
17 
(5.1%) 
296 
(87.3%) 
43 
(12.7%) 
143 
(51.4%) 
135 
(48.6%) 
177 
(53%) 
157 
(47%) 
187 
(56%) 
147 
(44%) 
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Appointment 
keeping 
Smoking cessation Alcohol use 
Diet 
recommendations 
Sun protection Physical activity 
Adherent 
Not 
adherent 
Adherent 
Not 
adherent 
Adherent 
Not 
adherent 
Adherent 
Not 
adherent 
Adherent 
Not 
adherent 
Adherent 
Not 
adherent 
Australia 
45 
(88.2%) 
6 
(11.8%) 
51 
(100%) 
0 
(0%) 
33 
(64.7%) 
18 
(35.3%) 
16 
(61.5%) 
10 
(38.5%) 
32 
(62.7%) 
19 
(37.3%) 
28 
(54.9%) 
23 
(45.1%) 
Brazil 
87 
(89.7%) 
10 
(10.3%) 
93 
(95.9%) 
4 
(4.1%) 
98 
(98%) 
2 
(2%) 
40 
(56.3%) 
31 
(43.7%) 
64 
(68.1%) 
30 
(31.9%) 
39 
(45.9%) 
46 
(54.1%) 
Chi-square 
test results 
2(10, N=1376) = 
17.91, p=0.056 
2(10, N=1369) = 
27.11, p=0.003 
2(10, N=1394) = 
146.21, p<0.001 
2(10, N=964) = 31.22, 
p=0.001 
2(10, N=1349) = 
56.24, p<0.001 
2(10, N=1340) = 
40.67, p<0.001 
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Figure 7.3: Country-wise investigation of non-adherence prevalence
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Discussion 
This study is the largest ever to investigate the prevalence of non-adherence to various 
non-pharmacologic components of the post-HTx regimen in the same sample. Its 
multinational set-up allows examination of inter-country variability in non-adherence 
prevalence. 
The highest overall prevalence of non-adherence was noted for physical activity: 44.1% 
(observed/unadjusted rate)–more than double the prevalence in the general global adult 
population (23%) (17). As insufficient activity is a major risk factor for several chronic diseases 
(17), including those that HTx recipients are at a higher risk of developing due to lifelong 
immunosuppressant intake, HTx recipients would benefit from interventions promoting 
physical activity. A meta-analysis (18) of 10 RCTs showed that cardiac rehabilitation programs 
could improve exercise capacity; however, most included studies focused on the immediate 
post-transplant period and did not investigate the programs’ possible spin-off effects, e.g., 
higher physical activity levels in daily life. I.e., physical activity is a poorly investigated domain 
in HTx.  
Next, 39.5% of our sample did not always apply sun protection when needed. As the 
prevalence of skin cancer in adult HTx recipients is 9.5% and 18.4% at 5 and 10 years post-HTx 
(19), respectively, strategies that boost sun protection use may help to prevent skin cancer. 
Unfortunately, research on such interventions within transplantation is still in its infancy. 
The third-highest non-adherence prevalence was for diet (37.8%). Poor dietary habits, 
e.g., high caloric intake, can lead to overweight and obesity, which increase the burden of 
chronic illness in the general population (20) (e.g., diabetes, hypertension). Yet, the question 
of whether overweight and obesity negatively impact post-HTx clinical outcomes also remains 
controversial. Most studies focusing on body mass index (BMI) at time of transplant have 
found an elevated risk for graft loss and mortality in HTx recipients with morbid obesity only 
(BMI>35), but not in groups having a low BMI at transplantation (21). Still, many patients gain 
weight post-HTx: one prospective registry study (22) reporting overweight and obesity in 
respectively 37% and 13.6% of patients at 3 years after HTx, which might ultimately elevate the 
risk for chronic disease. Unfortunately, few dietary interventions have been tested in 
transplant patients, leaving ample room for new evidence on how to effectively support healthy 
eating in HTx recipients (23). 
Fourth, heavy alcohol use was observed in 21.1% of the participants. One might argue 
that we used a very stringent definition; however, we followed CDC guidelines (14), which state 
that exceeding the specified limit increases the risk for over 200 diseases and injuries, 
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including liver disease, cardiovascular disease, and some forms of cancer (24). Unfortunately, 
alcohol-related research in transplantation focuses predominantly on liver transplant patients: 
the HTx literature is sparse. It remains unclear whether heavy alcohol use after HTx will affect 
graft or patient survival. 
Fifth, 6.6% of our sample smoked post-transplant. While in line with previously 
reported numbers (7, 25), this prevalence is presumably underestimated, bearing in mind that 
we used self-report to document smoking (26). Given that post-transplant smoking 
significantly reduces graft and patient survival (27, 28), we recommend that HTx programs 
regularly assess patients’ smoking status via more objective means, e.g., exhaled CO 
measurement, and should implement effective smoking cessation programs (28). 
Finally, appointment non-adherence was observed in 5.1% of the sample, which is 
similar to previously reported numbers (7, 29). Although the prevalence is relatively low, 
missing scheduled clinic visits after HTx is a risk factor for poor medication adherence, which 
elevates the risk for late acute rejections (29). Therefore, transplant programs should do their 
best to reach out to HTx recipients who might miss or drop out of follow-up care. 
In addition, we observed significant inter-country variability in non-adherence 
prevalence. The reasons behind this are open to speculation. E.g., alcohol use at social 
occasions might be more common and acceptable in some countries. Likewise, patients might 
wrongfully assume that sun protection is less important in countries with cooler temperatures 
or fewer hours of sunshine. Summarizing the evidence on possible factors of non-adherence 
prevalence variability between countries for each studied behavior is beyond the scope of this 
paper. Based on these examples, however, it is clear that not only individual patient 
characteristics, but also factors related to the patients’ communities, healthcare providers, 
healthcare settings or policies, or cultural aspects might contribute to the observed differences. 
Therefore, future studies should use a multilevel approach to understand variability (11), 
incorporating all potentially relevant correlates of each relevant health behavior at the patient, 
micro, meso and macro levels into a single model. 
Limitations and strengths of the study 
First, non-adherence was measured through self-report. Given the multitude of 
variables collected in the main study, the large sample size, and the multinational nature of the 
study, this was unavoidable. Second, the cut-off points used to categorize patients as 
adherent/non-adherent were chosen based on criteria that might not be clinically meaningful 
for the HTx recipient population. This was necessary in the absence of recommendations 
regarding appropriate levels of the investigated health behaviors for HTx recipients. Third, 
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HTx recipients were recruited and data collected during follow-up clinic visits. This might have 
skewed certain results, e.g., regarding appointment non-adherence, due to the possibility of 
including more adherent participants. Fourth, centers participated on a voluntary basis and 
could only participate if they performed at least 10 procedures, on average, per year. Smaller 
centers might organize follow-up care differently, or might lack the experience or resources to 
monitor adherence or lifestyle factors, possibly resulting in higher non-adherence rates than 
those documented in the present paper. Finally, the design of the study was cross-sectional, 
giving a static rather than a dynamic picture of non-adherence over time (30). 
Strengths include our large multinational sample. Moreover, studying all non-
pharmacologic components of the post-transplant regimen in the same patients is unique and 
allows a clear understanding of the corresponding adherence issues in HTx recipients. The use 
of random sampling at the patient level, applying the same non-adherence measures and 
operational definitions and our adjustment of prevalence rates to ensure appropriate 
representativeness of each country in relation to the entire sample (based on its HTx recipient 
population) further strengthen our belief that the numbers presented in this paper accurately 
depict the magnitude of the problem. 
To summarize, HTx recipients’ non-adherence to the non-pharmacologic components 
of the treatment regimen appears to be a major problem. By displaying the prevalence by 
behavior as well as by country, we hope our results will help clinicians prioritize their needs 
regarding tailored adherence-enhancing interventions. 
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Synthesis and discussion 
In light of the escalating global prevalence of chronic conditions (1), healthcare 
practitioners, researchers and policy makers are facing new challenges in the 21st century. One 
of these is the treatment burden of chronically ill patients (magnitude and duration) and its 
consequence, treatment non-adherence (2, 3). With scientists constantly pursuing better 
individual and societal outcomes and in view of the established worsening effect of treatment 
non-adherence on these outcomes (4), the field of multidisciplinary adherence research has 
emerged. It seeks to understand the causes and effects of differences between the prescribed 
and actual exposure to treatments (5) and, consequently, to intervene by developing solutions 
to minimize these differences. Although treatment adherence has been a research topic for over 
50 years, non-adherence to long-term therapies remains a major problem (6). A recent meta-
analysis of 771 medication adherence-enhancing intervention trials confirmed that there is still 
much room for improvement (7).  
Accordingly, this dissertation was written to cover some identified knowledge gaps, 
with the ultimate goal of contributing to better treatment adherence and, hence, better 
outcomes. This chapter will discuss the findings/outcomes of the dissertation from a broader 
perspective, with reflections on the greater challenge facing health systems, that is achieving 
better outcomes. In order to form an overview of the key findings/outcomes of the dissertation 
before going into detail, they are summarized here. They are: 1) developing EMERGE 
(European Society for Patient Adherence, COMpliance, and Persistence Medication Adherence 
Reporting Guideline), 2) non-adherence to post-HTx (heart transplantation) medication was 
prevalent in all the investigated phases and dimensions and was significantly higher in co-
medications than in immunosuppressants, 3) with regard to pre- and post-HTx adherence 
management practice patterns, questioning patients was the most commonly used adherence 
assessment method, and the frequency of using almost all adherence interventions decreased 
post-HTx, and 4) non-adherence to the post-HTx non-pharmacologic treatment occurred in 
all the investigated health behaviors, in almost all country-behavior combinations, more 
frequently in some behaviors than in others, and more frequently in some countries than in 
others. 
 
8.1 Discussion 
Although health systems with their components of health research and healthcare (8) 
are endeavoring to improve the health-related welfare status of individuals and societies (9), 
not all efforts necessarily lead to this end. A classic example on this is the contrast between a 
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country’s health expenditure as a percentage of its gross domestic product (GDP) and the 
country’s population health indicators. For example, countries that ranked high on the list of 
health expenditure in 2015 include: Sierra Leone (2nd, 18.32% of GDP) and USA (3rd, 16.84% 
of GDP) (10). In the same year, these countries were ranked 243rd and 49th respectively in 
terms of life expectancy at birth (11). The reasons for this disparity and inefficiency in the 
health systems are multiple. Two proposed reasons are considered here and the 
findings/outcomes of the dissertation are discussed within the scope of these reasons, which 
are: the usability of health research and the usefulness of healthcare. 
8.1.1 The Usability of Medication Adherence Research and EMERGE 
As far as the usability of health research results is concerned, there are currently grave 
concerns about health research waste (12). Two of the most prominent efforts to raise these 
concerns are the series “Research: increasing value, reducing waste” published in the journal 
The Lancet (13) and the series “Challenges in irreproducible research” in the journal Nature 
(14). One of the five publications included in the former was dedicated to waste from 
incomplete or unusable reports of biomedical research (15). In this paper, the authors make a 
clear statement on the usability of research reports, stating that “all readers have the right to 
expect that reports of research will be usable and that basic information will be completely and 
transparently reported”. In order to clarify the magnitude of the problem, they provided 
estimates of the prevalence of some reporting issues in all biomedical research study designs. 
In publications of trials, for example, they estimated that 38% of the abstracts did not mention 
effect sizes and confidence intervals, 40–89% of the methods sections described treatments 
inadequately, 50% of the results sections described efficacy outcomes incompletely, and 50% 
of the discussion sections did not systematically set new results in the context of previous trials. 
Another way of investigating problems in research reporting, other than a study’s 
design, is by investigating reporting problems within a certain topic of research, which in the 
scope of this dissertation is medication adherence. Inconsistency in reporting medication 
adherence research has been observed in many published research articles (16–22). The most 
fundamental reporting problem is the identification and definition of the behavior of the 
medication-taking process on which the research focuses (5, 19). Failing to define and identify 
the specific adherence behavior can lead to inappropriate measurement of the behavior, 
suboptimal data analysis, and insufficient reporting and misinterpretation of the results. 
Clearly, this failure affects the four questions research reports should answer (23), which are: 
what questions were addressed (target behavior) and why, what was done (measurement and 
analysis), what was shown (results) and what the findings mean (interpretation of the results), 
rendering research reports (publications) unusable. Accordingly, the first aim of this 
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dissertation was to develop a guideline for reporting medication adherence research that 
emphasizes the importance of accurate definition and description of the target medication-
taking behavior as the starting point of the research chain. 
Hence, the cornerstone of EMERGE is a medication adherence taxonomy (5) that 
updates the understanding of the construct by defining it as a process of taking medication. 
Contrary to prior definitions (6, 24, 25), which considered medication adherence as the degree 
or extent to which a patient’s medication-taking behavior coincides with a clinical prescription, 
viewing medication adherence as a process emphasizes its dynamic and multifaceted nature 
(19, 26). In fact, the taxonomy (5) conceptualizes medication adherence as a multi-component 
construct, starting with the initiation of the treatment (i.e., taking the first dose of the 
prescribed medication), moving on to the implementation of the medication regimen (i.e., 
administering the medication regimen according to the prescribed dose and time), and ending 
with discontinuation where the third phase (persistence) represents the length of time between 
initiation and the last dose. This conceptualization allows for an accurate identification of the 
target behavior, and correspondingly suitable measurement and corrective action (27). 
Although it was published six years ago (5) and has been widely cited in over 400 
articles since then (28), the use of this taxonomy as a basis for adherence research remains 
limited. Indeed, such conceptualization is rarely applied to reporting medication adherence 
research. In transplantation research, for example, a review of the literature published from 
January 2013 to April 2018 reveals that only just over 10 publications actually used the 
taxonomy when reporting their results. This is the role of EMERGE: a guideline that 
encourages the use of the taxonomy in reporting medication adherence research. Anticipation 
has been building since the protocol of developing EMERGE was published (29). Based on 
previous evidence on using other health research reporting guidelines (30), it is envisioned 
that the use of EMERGE will help in much the same way to produce more transparent and 
consistent reporting of medication adherence research. In this way, it will add more utility to 
results of research in this field, reduce its waste, advance the research field, and ultimately 
move in the direction of better patient and societal outcomes. Only with a systematic approach 
to studying medication adherence can this research field proceed in the right direction and at 
the right rate. 
8.1.2 Beyond usable medication adherence research: useful healthcare 
for HTx recipients 
While complete research reports are usable and form a good basis for evidence-based 
practice (31), another form of research waste and a reason for the inefficiency of health systems 
is the gap between research and real-world settings. As illustrated in figure 8.1, it is estimated 
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that it takes more than 15 years to harness 32% of published research to the benefit of patient 
care (32). One reason that has been suggested for this waste is the often unidirectional nature 
of the evidence pipeline (33) in which practitioners are regarded simply as recipients of 
research. This is aggravated by the misalignment of researchers’ motivations with those of 
research users and the disorientation of the incentives system (34, 35). This combination of 
factors leads to a gap between the evidence generated and real-world settings, which impedes 
the applicability of research in daily practice. As a result, evidence-based practice might not 
necessarily be effective (36) or sustainably effective.  
Indeed, in the delivery of healthcare in real-world settings many factors in the 
environment in which it is going to be delivered must be considered. Careful attention needs 
to be paid to all factors that ensure the effectiveness and sustainability of healthcare early in 
the stages of designing this healthcare (33). In light of the limited resources, only health 
technologies that prove to be effective and resource-efficient will be allowed to reach patients 
as decision makers are striving to ensure that treatments achieve their promised outcomes (37, 
38). This is where the role of implementation science comes in: it is, Bauer et al. state, “the 
scientific study of methods to promote the systematic uptake of research findings and other 
evidence-based practices into routine practice, and, hence, to improve the quality and 
Figure 8.1: The leakage points in the flow of original research into practice and the lag time 
between points; Green et al. 2008 
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effectiveness of health services” (37). It serves to ensure the compatibility of healthcare and the 
environment in which it will be implemented. Within this discipline, several frameworks have 
been proposed in an attempt to promote effective implementation through addressing all 
factors that might facilitate or hinder reaching the desired outcomes in a systematic way. 
Among these frameworks is the Consolidated Framework for Implementation Research (CFIR) 
(39) that combines and standardizes constructs from prior implementation frameworks. 
Figure 8.2 shows the various domains and constructs of the CFIR. 
 
In order to ensure the effectiveness and sustainability of healthcare delivery to the 
dissertation’s population of interest (HTx recipients), this implementation science approach 
needs to be applied early in the design of their healthcare. For as much as their treatment 
regimen is complex, their healthcare has to be tailored to their needs and adapted to the 
characteristics of the environment in which it is going to be delivered. BRIGHT, having 
surveyed HTx patients, clinicians, and center directors, has information from various 
stakeholders and provides a good overview of the HTx professional healthcare environment as 
a whole. Conducted in 36 HTx centers in 11 countries on four continents, the study uses a 
representative sample that provides insights into real-world practice. Accordingly, information 
gained from BRIGHT can highlight opportunities for improvement in HTx-recipient 
professional healthcare. Based on this, factors investigated in this dissertation are mapped to 
the CFIR framework to uncover system leverage points that are important for planning 
adherence-enhancing care for HTx recipients. 
 
Figure 8.2: The Consolidated Framework for Implementation Research; Damschroder et al. 
2009 
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8.1.3 Mapping the needs of HTx recipients and characteristics of their 
professional healthcare using BRIGHT 
Table 8.1 summarizes the mapping of certain constructs from CFIR to the findings of 
chapters 5—7. Hereinafter, this mapping is explained and reflected upon. 
8.1.3.1 Intervention characteristics 
In this category, findings in the dissertation inform two constructs from CFIR. First, in 
chapters 5 and 7, having a representative sample of HTx recipients increases the confidence 
that the prevalence estimates of non-adherence that were obtained are generalizable and can 
help decision makers understand the aggregate relative advantage of implementing an 
intervention. This advantage can be measured in terms of improvement in patient outcomes 
or reduction in healthcare-associated resource use. For example, a decision maker, without 
additional information on a specific setting, can use the prevalence estimates reported in 
chapters 5 and 7 to determine the approximate number of HTx recipients who are non-
adherent to a specific treatment component. Combining this number with evidence on 
outcomes or resource-use associated with using a certain adherence-enhancing intervention 
for this treatment component, the decision maker can have a preliminary estimate of the net 
effect of using the intervention at the level of his/her setting. 
Furthermore, chapter 7 can inform the adaptability of post-HTx management of 
adherence. By investigating post-HTx non-pharmacologic treatment non-adherence 
prevalence at the country level, this chapter shows non-adherence patterns in each of the 11 
countries participating in the BRIGHT study. As a result, it allows each country to tailor its 
post-HTx healthcare to meet the needs of its local HTx recipients. For example, in Brazil, non-
adherence to physical activity was most prevalent, while it was non-adherence to sun 
protection in the United Kingdom. 
8.1.3.2 Outer setting 
As far as the outer setting is concerned, findings from chapters 5 and 7 can be mapped 
to patient needs and external policy. Firstly, chapters 5 and 7 provide information on patient 
needs with regard to management of adherence. While these results are not a direct elicitation 
of the needs, estimates of prevalence of non-adherence can form a good starting point from 
which to understand them. For example, chapter 5 provided prevalence estimates of non-
adherence to immunosuppressants and co-medications. It investigated medication non-
adherence in two of the three phases (5) (implementation and persistence) and, subsequently, 
in four dimensions of the implementation phase. Specifying the actual medication-taking 
behavior investigated, providing an operational definition of it and accordingly comparing the 
 143 | P a g e  
 
corresponding non-adherence prevalence estimates helps to identify patient needs with regard 
to medication adherence-enhancing interventions. For instance, Zullig et al. provide the 
example that reminder systems help more with implementation than with persistence issues 
(40). The same applies to the non-pharmacologic treatment, where non-adherence was 
investigated in all of the treatment components. In this way, the choice of adherence-
enhancing intervention for HTx recipients can be informed by findings from chapters 5 and 7. 
Moreover, all the comparison MNA dimensions had significantly higher percentages of 
HTx recipients not adhering to co-medications than to immunosuppressants. The reasons 
behind this significant difference remain to be investigated. Nevertheless, the difference is in 
line with prior studies in other transplant (41) and chronically ill patient populations (42), 
suggesting the concept of self-regulation (43) where patients use mental categories to classify 
their medications and adapt their medication intake accordingly to fit their lifestyle. If proven 
true in HTx, this interpretation should be taken into consideration when designing adherence-
enhancing interventions for post-HTx care. Given the established association of higher health 
literacy (44) and medication necessity (45) with medication adherence, HTx recipients must 
be made aware of the importance of all post-HTx medication to their health. 
As far as external policy is concerned, significant variability was observed in non-
adherence prevalence between countries in all treatment components except follow-up visits. 
This aligns with the assumption that the health behavior of HTx recipients depends on their 
macro environment (6, 46) and calls for a tailoring of the selected adherence-enhancing 
interventions to the corresponding setting in which they will be implemented. Considering the 
limited data on system factors included in this dissertation, this recommendation confirms the 
framework rather than specifies the actual factors according to which adherence-enhancing 
interventions should be tailored. 
8.1.3.3 Inner setting 
Within the inner setting, findings from the dissertation can inform intervention 
development on structural characteristics and implementation climate. More specifically, 
chapter 6 provides information on the type of transplant centers where HTx recipients receive 
their follow-up care, as the majority (83.3%) were university teaching hospitals. Moreover, this 
chapter shows the average general and HTx-specific years of experience of HTx clinicians and 
their certification in HTx, all factors that might facilitate or hinder the implementation of 
interventions (47). 
With regard to the implementation climate, findings from chapter 6 and chapters 5 and 
7 can provide information on compatibility and relative priority, respectively. In the case of 
compatibility, chapter 6 highlighted the point that questioning patients (self-report) about 
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their medication adherence was the most commonly used adherence assessment method along 
the HTx continuum, while electronic monitoring was used by only 2.8% short-term (<1 year) 
post-HTx. This reflects the current general view of self-report as a practical measure for use in 
everyday clinical practice (48-50), despite its susceptibility to social desirability and memory 
biases (50). Electronic monitoring, on the other hand, is reliable yet expensive to implement 
on a large scale (51, 52). For this reason, healthcare strategies for managing HTx-recipients’ 
medication adherence in resource-limited settings should consider using self-report to ensure 
the feasibility of their implementation. 
In addition, a general theme of the decreasing use of adherence-enhancing 
interventions beyond one year post-HTx was observed. Given that prior research has shown 
that the more time that has elapsed post-HTx, the higher the prevalence of 
immunosuppressant non-adherence (53), adherence-enhancing interventions need to be 
planned and integrated in long-term HTx follow-up care. One might argue that the frequency 
of scheduled outpatient follow-up visits naturally decreases with time after transplantation as 
HTx recipients become more independent and stabilized. This is where the need for decision 
makers to cooperate with other healthcare professionals who remain in long-term contact with 
HTx recipients becomes vital. Indeed, a multidisciplinary approach has been suggested as an 
effective way of tackling medication adherence in general and in transplantation (54–57) in 
particular. However, considering the observed underestimation of MNA by healthcare 
professionals (58, 59) and in light of the abovementioned findings, empowering them with 
adequate measures of adherence is a key to successful identification and support of non-
adherent HTx recipients. Researchers can contribute to this endeavor by developing more 
accurate measures that fit into daily practice. 
With regard to relative priority, chapter 5 showed that MNA happened more frequently 
in the taking (immunosuppressants 17.3% and co-medications 23.9%) and timing dimensions 
(immunosuppressants 28.7%) than in other dimensions. Likewise, chapter 7 showed that non-
adherence to physical activity was the most prevalent (47.8%), followed by sun protection 
(39.9%), diet recommendations (38.2%), limiting alcohol consumption (22.9%), smoking 
cessation (7.4%), and follow-up visits (5.7%). While these findings are meant to inform 
decision makers of which treatment components should be given priority for targeting with 
adherence-enhancing interventions, caution should be exercised before deciding on priorities 
using prevalence information only. For example, although just 7.4% of the sample were not 
adherent to smoking cessation, it is wise not to label the behavior as a low priority and ignore 
smoking HTx recipients as the association between smoking and poor transplant outcomes is 
widely established (60–62). 
 145 | P a g e  
 
Whether decision makers are able to decide on the most important behaviors to target 
with adherence-enhancing interventions using either the prevalence of non-adherence or the 
strength and effect size of the association between non-adherence and outcomes is debatable. 
Admittedly, we need more research in order to make fully-informed resource-efficient 
decisions regarding the use of adherence-enhancing interventions. First, we need better 
adherence measures for all treatment components (tailored to the HTx-recipient population) 
that are both sensitive and specific enough to accurately identify adherent and non-adherent 
patients and quantitatively describe their behavior with adequate granularity. Once we have 
such measures, we can conduct larger studies that correlate adherence levels with clinical 
outcomes to identify clinically meaningful adherence levels. Based on these findings, we can 
conduct intervention studies targeting non-adherent patients to determine the effect of the 
interventions on adherence- and patient-related outcomes. Once this has been done, we can 
conduct comparative cost-effectiveness studies for the interventions and judge them based on 
their resource needs and outcomes, using uniform measures. Only then, can information on 
non-adherence guide decision makers further by informing them of the anticipated 
population-wide outcomes and budget impact of using these interventions.  
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Table 8.1 Mapping dissertation findings (chapters 5-7) to some constructs of the Consolidated Framework for Implementation Research (CFIR) 
Construct 
Dissertation chapter 
Link 
Chapter 5 Chapter 6 Chapter 7 
Intervention characteristics 
- Relative advantage 
X  X 
Having reported generalizable prevalence estimates of non-adherence to all 
post-HTx treatment components, chapters 5 and 7 can help decision makers to 
understand the aggregate benefit to be gained from implementing adherence-
enhancing interventions. 
- Adaptability 
  X 
With its country-wise prevalence estimates of non-adherence to each treatment 
component, chapter 7 provides information that allows to tailor post-HTx 
management of adherence to the specific local needs of each country. 
Outer setting 
- Patient needs & resources 
X  X 
Chapters 5 and 7 provide specific information on patient needs in terms of 
treatment components (pharmacologic and non-pharmacologic) where non-
adherence occurs. 
- External policy and incentives 
  X 
Having shown significant differences between countries in non-adherence to 
five of the non-pharmacologic treatment components, chapter 7 emphasizes 
the need to consider system factors in designing adherence-enhancing 
interventions. 
Inner setting 
- Structural characteristics 
 X  
Chapter 6 provides certain structural information on the setting where follow-
up care for HTx recipients is delivered. 
- Compatibility (implementation 
climate) 
 X  
Chapter 6 provides information on the current practice patterns regarding 
management of medication adherence. 
- Relative priority (implementation 
climate) 
X  X 
Based on the prevalence of non-adherence to each treatment component 
discussed in chapters 5 and 7, decision makers can decide on the relative 
priority of target treatment components for adherence-enhancing 
interventions. 
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8.2 Limitations and strengths of the dissertation 
Beyond those discussed in individual chapters, two main limitations apply when 
discussing the findings of the dissertation in light of the presented framework (i.e., usable 
research and useful healthcare). The first limitation concerns EMERGE. Inasmuch as creating 
a new guideline for reporting medication adherence research paves the way for better reporting 
of the research, it is not a guarantee that all reports of adherence research will be perfect in all 
respects. Having a guideline available does not automatically translate to its use by all 
medication adherence researchers. A recent review of systematic reviews of adherence to 
reporting guidelines found that 86% of these reviews reported suboptimal levels of adherence 
to reporting guidelines (63). For this reason, in order to raise awareness of the guideline among 
the target audience (medication adherence researchers), the EMERGE steering committee will 
register the guideline on the EQUATOR (Enhancing the QUAlity and Transparency Of health 
Research) network and will encourage its adoption by authors and reviewers, and its 
endorsement by journals. 
Complementary to these efforts, other stakeholders could contribute to enhancing the 
usability of medication adherence research. For example, research funders could require 
research proposals to be conceptualized and written in EMERGE language. Policy and decision 
makers as well as clinicians could choose to select and implement adherence-enhancing 
interventions in their settings that are designed and evaluated according to EMERGE. This 
would have a feedback effect for researchers, allowing them to adapt their approach to the 
systematic one of EMERGE. Acknowledging the fact that much work needs to be done beyond 
creating a guideline, Glasziou et al. made three recommendations to funders and research 
institutions (15): 1) shifting regulations and rewards towards better and more complete 
reporting, 2) providing a reporting infrastructure that supports good reporting and archiving, 
and 3) training authors and reviewers on high-quality and complete reporting. Stated briefly, 
EMERGE is a step towards providing usable medication adherence research reports and 
reaching better medication adherence and outcomes. But it will only be effective if all 
stakeholders endorse its use. An interesting study is currently ongoing and we can learn from 
its future results (64). It aims to review interventions used to improve adherence to health 
research reporting guidelines in order to inform future decisions. 
The second limitation concerns applying the CFIR to chapters 5–7 and the HTx 
recipients’ representativeness at the country level. While HTx recipients were selected 
randomly and the countries included in the study are situated on four continents, HTx centers 
were selected conveniently. This limits the generalizability of results from the included HTx 
recipients in a certain country to the HTx-recipient population of this country. Consequently, 
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caution should be exercised before using country-level estimates in decision-making. Rather, 
these should be used to provide rough estimates, and in combination with estimates from the 
whole sample. For example, an Australian decision maker should avoid being tempted by the 
finding that no Australian HTx recipient was non-adherent to smoking cessation; instead, he 
or she should keep in mind that in the general HTx-recipient population non-adherence to 
smoking cessation is prevalent in 7.4%. 
Strengths of this dissertation include studying the treatment adherence topic 
systematically by distinguishing between the two main types of treatment regimens: 
pharmacologic and non-pharmacologic. Although there are many similarities in adherence to 
both treatment regimens and the two are usually interrelated (65, 66), non-pharmacologic 
treatment involves lifestyle changes that are contingent on personal will and commitment to 
achieving habit formation (67). Accordingly, studying adherence to each treatment regimen 
separately is believed to enhance our understanding of the corresponding behavior and, hence, 
to help in developing appropriate adherence-enhancing interventions. Furthermore, the 
dissertation covered knowledge gaps at the patient, healthcare practitioner (meso), and 
healthcare system (macro) levels. Although a patient-oriented approach is essential to 
achieving better treatment adherence, it should be system-based (6, 68, 69) and consider other 
factors beyond the patient. A factor that is rarely discussed as instrumental to adherence 
behavior and outcomes is adherence research. Given the current frameworks and models of 
health behaviors and the fact that adherence research is less closely related to adherence 
behavior than other factors (e.g., factors explained in the ecological model of medication 
adherence (68)), it may be easy to miss the importance of this component. This, however, 
should not prevent the exploitation of all possible opportunities to focus on all factors in 
reaching better adherence behavior and outcomes. Hence, the dissertation covered a 
knowledge gap at the level of medication adherence research/researchers. 
Strengths related to the specific sections of the dissertation include the applicability of 
EMERGE to many study designs and its development through a structured process following 
the recommended guidance (70), with input from topic experts from various disciplines and 
geographic locations. In the case of BRIGHT, strengths include the large and diverse 
multinational sample of 36 HTx centers from 11 countries and four continents and the study of 
all treatment components of the post-transplant regimen in the same patients. This allowed a 
clear understanding of HTx recipients’ post-HTx adherence profile and their professional 
healthcare with regard to the management of medication adherence. As HTx recipients were 
the focus of the study, the conceptualization of BRIGHT was based on the Integrative Model of 
Behavioral Prediction (IMBP), a health behavior model that is regarded as extremely useful in 
studying health behaviors, medication adherence included (71, 72). Considering the multi-
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faceted nature of medication adherence, BRIGHT further embedded the IMBP in an ecological 
model for medication adherence, which allowed for a more comprehensive understanding of 
the behavior. 
8.3 Conclusion 
Non-adherence to pharmacologic and non-pharmacologic treatments remains a 
challenge facing the healthcare system and all its stakeholders. This dissertation covered 
knowledge gaps at the level of patients, clinicians, policy/decision makers, and researchers. 
Sound reporting of medication adherence research using EMERGE could increase the quality 
and utility of medication adherence research. At the same time, understanding the current care 
context, including patients’ adherence profiles and the professional practice patterns regarding 
management of adherence, assists in the implementation of evidence-based practice guidelines 
in routine care. Enhancing the usability of research and the usefulness of healthcare will, 
ultimately, lead to better outcomes for individuals and their societies. 
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